EXOME SEQUENCING APPROACH TO IDENTIFY CAUSATIVE GENES FOR AMYOTROPHIC LATERAL SCLEROSIS by C. Tiloca
     
UNIVERSITÀ DEGLI STUDI DI MILANO 
 
SCUOLA DI DOTTORATO IN MEDICINA MOLECOLARE  
 
CICLO  XXVII 
Anno Accademico 2013/2014 
 
 
TESI DI DOTTORATO DI RICERCA 
Settore Scientifico Disciplinare MED/26 
 
EXOME SEQUENCING APPROACH 
TO IDENTIFY CAUSATIVE GENES  FOR 
AMYOTROPHIC LATERAL SCLEROSIS 
 
 
  Dottorando : Cinzia  Tiloca  
 Matricola  N°     R09756   
 
 
 
TUTORE: Ch.mo Prof. Giacomo Pietro Comi 
CO-TUTORE:  Ch.mo  Prof.  Vincenzo  Silani 
COORDINATORE DEL DOTTORATO: Ch.mo Prof. Mario Clerici
 
i 
 
ABSTRACT  
Introduction Amyotrophic lateral sclerosis (ALS) is an adult-onset 
neurodegenerative disorder caused by the loss of motor neurons in the 
cerebral cortex, brainstem and spinal cord. ALS occurs prevalently as 
sporadic forms (SALS), but a small proportion of cases (5-10%) displays a 
positive family history (FALS), generally with an autosomal dominant 
pattern of inheritance. To date, more than 20 causative genes have been 
identified in FALS, providing fundamental insights into the pathogenic 
mechanisms and underlying the great genetic heterogeneity of the disease. 
Despite these numerous advances, the genetic basis of nearly 40% of 
FALS remains to be identified, while the genetic component of SALS is 
largely unknown. A powerful and innovative tool for genetic studies in ALS 
is represented by next-generation sequencing and in particular by the 
targeted sequencing of the coding part of the genome or exome. 
Aim of this research project was to identify novel genes associated to FALS 
and SALS by applying complementary approaches all based on exome 
sequencing, which overcomes the limitations of traditional genetic 
strategies.  
Methods Three different disease gene identification strategies were 
applied: I) exome sequencing associated to linkage analysis in two large 
ALS dominant pedigrees; II) exome-wide rare variant burden analysis on 
363 unrelated index FALS cases; III) exome sequencing of 32 SALS and 
their unaffected parents (trio-design).  
Results I) By performing exome-sequencing in combination with linkage 
analysis, we identified PFN1 (profilin-1), encoding for a protein regulating 
actin dynamics, as a novel ALS-causative gene. Mutations in PFN1 were 
observed in ~2.6% of FALS and functional studies demonstrated 
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aggregation propensity, reduction of actin binding ability and axonal 
outgrowth inhibition of mutant PFN1 proteins. 
II) As a result of the unbiased case-control rare variant analysis, applied on  
a total 12.495 genes, we identified TUBA4A (Tubulin, Alpha 4a) as 
candidate gene showing a statistically significant excess of rare damaging 
variants in 363 index FALS cases sequenced. Functional analysis revealed 
that ALS-related mutants were defective in forming alpha/beta tubulin 
dimers in vitro and in incorporating into microtubules in vivo. In addition, the 
truncated mutant TUBA4A p.W407X showed aggregation propensities.        
III) By sequencing the exomes of 32 SALS patients and their unaffected 
parents, we identified 25 de novo mutations (DNMs) in 16 of 32 trios, with 
an overall DNM rate of 0.78. Although we did not find recurrently mutated 
genes in our ALS trios, bionformatic analysis showed potential inter-
connections between the candidate genes. Functional classification 
revealed that DNMs are enriched in genes encoding for proteins involved in 
transport and in GTPase regulatory activity.  
Conclusions  Our findings indicate that exome-sequencing, combined with 
different strategies for study design and data analysis, is an effective and 
successful approach for the identification of novel ALS causative genes. 
The identification of PFN1 and TUBA4A genes, encoding for proteins 
implicated, respectively, in actin polymerization and microtubule formation, 
further supports a major role of cytoskeletal defects in ALS pathogenesis.  
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SOMMARIO  
Introduzione La Sclerosi  laterale amiotrofica (SLA) è una malattia 
neurodegenerativa progressiva e fatale caratterizzata dalla perdita selettiva 
dei motoneuroni nella corteccia cerebrale, nel tronco cerebrale e midollo 
spinale. La maggior parte dei casi è costituita da forme sporadiche, mentre 
solo il 5-10% dei casi è rappresentato da forme familiari, causate da geni 
con modalità di trasmissione mendeliana, generalmente autosomica 
dominante. Sono stati identificati più di 20 geni causativi delle forme 
familiari, che hanno contribuito a comprendere meglio i meccanismi 
patogenetici coinvolti e sottolineano la grande eterogeneità genetica della 
malattia. Nonostante i numerosi progressi raggiunti, in circa il 40% dei casi 
familiari la causa genetica non è stata ancora identificata, mentre la 
componente genetica delle forme sporadiche è in gran parte sconosciuta. 
L’ applicazione delle tecniche di sequenziamento di nuova generazione ed 
in particolare il sequenziamento della porzione codificante del genoma o 
esoma rappresenta un approccio innovativo e promettente per gli studi 
genetici sulla SLA. Lo scopo del presente progetto di ricerca di Dottorato è 
stato quello di identificare nuovi geni associati alle forme familiari e 
sporadiche di SLA mediante sequenziamento dell’esoma come metodo 
alternativo per superare i limiti delle tecniche genetiche tradizionali.   
Metodi  Sono state utilizzate tre diverse strategie per l’identificazione di 
geni causativi: I) sequenziamento dell’esoma in combinazione con analisi di 
linkage in due grandi  famiglie SLA a trasmissione dominante; II) analisi per 
varianti rare degli esomi di 363 casi familiari singoli; III) sequenziamento 
dell’esoma in 32 casi di SLA sporadica e dei loro genitori non affetti 
(approccio dei trios).                                                                                     
Risultati  I) Attraverso l’approccio combinato di sequenziamento 
dell’esoma ed analisi di linkage, abbiamo identificato il gene PFN1 
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(profilina-1), codificante per una proteina implicata nella regolazione 
dell’actina, come     nuovo gene causativo di SLA. Mutazioni a carico del 
gene PFN1 sono state osservate nel  2,6% dei pazienti SLA familiari e gli 
studi funzionali condotti sui mutanti hanno dimostrato una maggiore 
tendenza all’aggregazione, una riduzione del legame all’actina ed un effetto 
inibitorio sulla crescita assonale.  
II) L’analisi delle varianti rare tra casi e controlli, applicata su un totale di 
12.495 geni, ha portato all’identificazione di TUBA4A (codificante per lalfa-
tubulina 4a) come gene candidato caratterizzato da un eccesso 
significativo di varianti rare potenzialmente dannose nei 363 casi familiari 
analizzati. L’analisi funzionale ha dimostrato per i mutanti di TUBA4A una 
capacità ridotta di dimerizzazione con la beta-tubulina in vitro ed un’alterata 
incorporazione nei microtubuli in vivo. Inoltre, il mutante tronco TUBA4A 
p.W407X ha mostrato una maggiore tendenza all’aggregazione.  
III) Infine, analizzando l’esoma di 32 pazienti con SLA sporadica e dei loro 
genitori non affetti, abbiamo identificato 25 mutazioni de novo in 16 dei 32 
trios analizzati, con un tasso di mutazioni de novo pari a 0,78.  Non sono 
stati identificati geni con molteplici mutazioni de novo nei trios sequenziati, 
ma le analisi bioinformatiche hanno mostrato possibili connessioni tra i geni 
candidati e la classificazione funzionale ha rilevato che le mutazioni de 
novo sono principalmente a carico di geni codificanti per trasportatori o per 
proteine con attività regolatoria sulle GTPasi. 
Conclusioni  I risultati ottenuti hanno dimostrato che il sequenziamento 
dell’esoma, applicato con specifiche strategie di studio e di analisi, è un 
approccio efficace per l’identificazione di nuovi geni causativi nella SLA.    
La scoperta dei due geni PFN1 e TUBA4A, codificanti per proteine 
coinvolte nel processo di polimerizzazione dell’actina e dei microtubuli, 
fornisce ulteriori evidenze a supporto del coinvolgimento del citoscheletro 
nella patogenesi della SLA.  
v 
 
TABLE OF CONTENTS 
1. INTRODUCTION          1 
1.1 Amyotrophic Lateral Sclerosis (ALS)      1 
1.1.1   Epidemiological and clinical features       3 
1.1.2   Clinical diagnosis        8 
1.1.3   Etiology of ALS       10 
1.1.4   Role of enviromental risk factors    11 
1.2 Genetics of ALS       14 
1.2.1   Causative genes      14 
1.2.2   Genetic risk factors      20 
1.2.3   Methodologies used to identify  ALS genes   22 
1.2.3.1 Linkage analysis       22 
1.2.3.2   Candidate gene approach      23 
1.2.3.3   Genome-wide association studies    24 
1.2.3.4   Whole-exome sequencing     26 
1.2.4   Problems and limitations in the genetic    
     study of ALS       28 
1.3  Pathogenic mechanisms       30 
1.3.1  Protein aggregation      30 
1.3.2  RNA metabolism       31 
vi 
 
1.3.3  Mitochondrial dysfunction      32 
1.3.4  Cytoskeletal abnormalities     32 
 
2. AIM OF THE PROJECT       34 
 
3. METHODS AND MATERIALS      35 
3.1  Patients and controls      35 
3.2  Linkage analysis and exome sequencing   39 
3.3  Data analysis strategies      40 
3.4  Bioinformatic analysis      42 
3.5  Sanger sequencing and genotyping    43 
3.6  Cell cultures        45 
3.7  Immunofluorescence      46 
3.8  Soluble/insoluble fractionation      47 
3.9  Immunoprecipitation      48 
3.10  Tubulin dimerization assay      48 
 
4. RESULTS         49 
4.2 Exome  sequencing  of  ALS families identifies           
 mutations in PFN1 gene      49 
4.2 PFN1 mutants are aggregation prone and show 
 alterations in actin binding      55 
vii 
 
4.3 Exome-sequencing   of  unrelated  FALS  indentifies  
           TUBA4A as candidate gene     61 
4.4 TUBA4A  mutants affect  microtubule  polymerization   66
       
4.5   Identification of de novo mutations using a trio-based 
exome sequencing approach     72 
 
5. DISCUSSION        79 
6. CONCLUSIONS        85 
7. REFERENCES        87    
8. ACKNOWLEDGMENTS               100 
9. SCIENTIFIC PRODUCTION              101 
 
 
 
 
1 
 
1. INTRODUCTION 
1.1  Amyotrophic Lateral Sclerosis (ALS)  
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal adult-onset 
neurodegenerative disorder characterized by the loss of motor neurons in 
the cerebral cortex, brainstem and spinal cord. The main clinical features of 
the disease include progressive weakness, wasting and paralysis of 
skeletal muscles [1]. In ALS both upper motor neurons (UMNs) and lower 
motor neurons (LMNs) are affected: UMNs cell bodies are located within 
the primary motor cortex (precentral gyrus) and project their long axons to 
the lower motor neurons via the corticospinal and corticopontine/bulbar 
tracts; LMNs are located within the motor nuclei of cranial nerves in the 
brainstem and the anterior horn of the spinal cord, and directly innervate 
skeletal muscles (Figure 1). The clinical symptoms depend on the different 
involvement of UMNs and LMNs. Symptoms of UMNs involvement include 
spasticity, hyperreflexia and the presence of abnormal reflexes (Babinski's 
sign). Symptoms of LMNs degeneration include muscle weakness and 
atrophy, muscle cramps, and fasciculations [2]. The term “Amyotrophic 
Lateral Sclerosis” was originally introduced in 1874 by the famous French 
neurologist Jean-Marie Charcot, who was the first to accurately provide a 
complete clinical description of the disease, correlating the clinical signs 
with anatomo-pathological findings [3]. “Amyotrophic” refers to the atrophy 
of muscle fibers, and “lateral sclerosis” describes the specific sclerotic 
changes in the lateral tracts of the spinal cord due to the degeneration of 
the corticospinal tracts with reactive astrogliosis.   
Considering the great advancements of Jean-Marie Charcot in describing 
its clinical and pathological features, ALS is still referred to as Charcot’s 
disease in many parts of the world [4].   
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Figure 1. Anatomical organization of the human motor systems. The 
upper motor neurons (UMN), originating from the motor cortex, form 
synapses with the lower motor neurones (LMN) in the motor nuclei of the 
brainstem and spinal cord.  
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1.1.1  Epidemiological and clinical features  
ALS is an adult-onset disease with an incidence of 1-2 /100.000 individuals 
per year in Caucasian populations and a lifetime risk of 1:400.  Incidence 
rate increases with age, reaching a peak between 60 and 80 years, and is 
higher in male than female  (male:female ratio of 1.5) [1]. 
A lower incidence rate has been reported in some ethnic populations 
(American Indians and Alaska natives), while it is 50-100 times higher in 
three geographical areas of the Western Pacific Ocean (Guam, Western 
New Guinea and Japan’s Kii Peninsula) [5]. In these geographical regions 
the extremely high incidence of ALS,  which often occur in combination with 
parkinsonism and dementia (ALS-PDC), seems to be caused by 
environmental factors, such as dietary exposure to β-methylamino-L-
alanine (BMAA) and high levels of mineral content in the soils and drinking 
water.  
The disease is clinically heterogeneous with an extremely variable clinic 
presentation as regards age of onset, disease duration, site of onset, 
relative mix of UMN and LMN deficits and other clinical features.               
The mean age of onset is between 55-65 years with a median age of onset 
of 64 years [6]. Only 5% of patients have symptom onset before 25 years of 
age: these cases are known as juvenile ALS (JALS) and usually present a 
slower disease progression and a mainly UMN phenotype. In ALS the 
death occurs from respiratory failure within 2-5 years from symptom onset 
(with a median survival of 3 years), but disease duration varies widely in 
individual patients, ranging from few months to over 10 years [7]. To date 
there is no effective treatment for the disease: the only drug approved by 
FDA is riluzole, which has been shown to increase survival by about 3 
months. 
Approximately 75-85% of ALS patients have a classical spinal onset of the 
disease, with a focal and unilateral muscle weakness starting distally or 
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proximally in the upper or lower limbs [8]. The frequency of upper limb 
versus lower limb involvement is approximately equal. Early signs include 
foot drop, difficulty in walking, loss of hand dexterity or weakness when 
lifting the arms. As disease progresses and limb function deteriorates, 
patients lose the ability of walking independently and become dependent 
on caregivers. About 25% of ALS cases show a bulbar onset, characterized 
by dysarthria, hypophonia with nasal voice, tongue fasciculations and 
dysphagia initially for liquids and subsequently for solids [8]. In bulbar 
patients, limb symptoms can appear almost simultaneously or can occur 
later, usually within 1-2 years. Bulbar onset, which is associated with a 
shorter survival, is more frequent in women and in older age groups: 43% 
of patients over the age of 70 present with bulbar symptoms compared to 
15% below the age of 30 [8]. A smaller proportion of individuals (~5%) 
experiences "respiratory onset" ALS, with initial involvement of the 
diaphragm and intercostal muscles.  
Other characteristic phenotypic variants of ALS, with a typical slower 
progression, include: the “flail arm” syndrome, which involves predominant 
muscle weakness in the proximal upper extremities and a relative sparing 
of lower limbs, and the “flail leg” syndrome or pseudopolyneuritic variant, 
which is characterized by symmetrical LMN signs within the distal 
segments of the lower extremities [9]. 
Other related forms of motor neuron disease include: a) primary lateral 
sclerosis (PLS) characterized by the exclusive affection of the UMNs; b) 
PMA (progressive muscular atrophy) resulting from the exclusive affection 
of LMNs; c) progressive bulbar palsy (PBP) in which  the lowest motor 
neurons of the brain stem are most affected. Long term follow-up of PLS 
and PMA cases has shown that patients, after a disease duration of six 
years or more,  may progress  to ALS, suggesting that these conditions 
should be considered variants of ALS [10]. 
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Symptoms often begin focally but with progression of disease they spread 
along continuous anatomic paths. Notably, two groups of motor neurons 
are relatively preserved until the late stages of the disease: the oculomotor 
nuclei in the brainstem and the Onuf’s nucleus in the sacral spinal cord, 
which innervates the external striate urethral and rectal sphincters [11]. 
Recently, researchers are investigating the difference in properties of these 
neuronal populations, to acquire novel insights into the mechanisms of 
neuronal degeneration, and to identify potential targets for therapeutic 
manipulation [12].  
Since the disease primarily involves motor neurons, sensory functions are 
generally preserved, although a minority of patients complains of some 
numbness and paresthesias. Abnormalities of sensory nerve conduction 
have been reported in a small number of patients with ALS but these 
findings often reflect the presence of an unrelated, coexistent condition [8]. 
 
Association with other clinical conditions 
The concept of ALS as a purely motor neuron disease has been surpassed 
by the increasing recognition that the disease may be associated with 
variable clinical conditions, such as cognitive impairment, FTD, aphasia, or 
parkinsonism [13]. 
Cognitive impairment in ALS was considered uncommon until recently, 
because it is often underreported by families and difficult for clinician to 
assess due to the presence of motor symptoms.  In Charcot’s original 
reports cognitive changes were not described, but cognitive and behavioral 
modifications (including irritability, delusions, and hallucinations) in isolated 
ALS patients were already reported in the late 1800’s. Additionally, 
histopathological studies of post-mortem tissues from few  ALS cases with 
dementia provided evidence of anatomical alterations in the cerebral cortex  
that could explain the cognitive changes observed clinically [14].  
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However, for a long time, clinicians continued to consider these 
observations as isolated and atypical cases, convinced that ALS patients 
remained cognitively normal until the terminal stage of the illness. Only in 
recent years it has been recognized that ALS is associated to a wide 
spectrum of behavioral, cognitive or language dysfunctions, which can 
precede, occur simultaneously or follow the motor symptoms.  
A mild cognitive impairment, affecting executive functions, cognitive 
flexibility and verbal fluency, is present  in 36%-51% of patients with ALS 
[15] but only a small group of cases (10-15%) shows a more severe 
dementia, which fulfills the clinical criteria for fronto-temporal dementia 
(FTD) [16].  
Second to Alzheimer's disease (AD) in prevalence, FTD is characterized by 
the progressive neuronal loss in the frontal and/or temporal lobes leading to 
a gradual impairment of behavior, language, and personality, with a relative 
preservation of memory, praxis, and visuospatial functions. The most 
common clinical phenotype of FTD associated with ALS is the behavioral 
variant (bvFTD) characterized by early and progressive changes in 
personality, with disinhibited, apathetic, or manifest stereotypical behaviors 
[15]. Individuals with ALS-FTD show a tipically onset in their 50’s and have 
a worse survival compared to patients with ALS or FTD alone [17]. In the 
last few years, this clinical overlap between ALS and FTD has been further 
supported by neuropathological and genetic findings that have been 
fundamental to recognize that ALS and FTD represent a disease 
continuum. In fact, ubiquitinated neuronal inclusions containing TAR DNA 
binding protein 43 (TDP-43) are the pathological hallmark of ALS (Figure 2) 
but occur also in a sub-population of patients with frontotemporal lobar 
degeneration with ubiquitin inclusions (FTLD-U) [18]. Similarly, a FUS 
pathology has been observed in a rare subgroup of FTLD patients and in 
LMNs of ALS cases carrying mutation in FUS gene [14]. Moreover, a 
hexanucleotide repeat expansion in the non-coding region of C9orf72 gene 
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has been identified recently as the most common cause of both ALS and 
FTD [20,21]. 
In other cases atypical clinical features, such as extrapyramidal signs, 
objective sensory loss, autonomic dysfunction, cerebellar degeneration, or 
ocular motility disturbance are reported in association with ALS phenotype. 
These forms occur rarely and are defined as ALS-plus syndrome [22]. 
 
 
Figure 2. Pathological Overlap of ALS and FTD. Pathological protein 
inclusions in ALS and FTD, according to the major protein misaccumulated. 
Inclusions of TDP-43 and FUS/TLS in ALS and FTD reflect the pathological 
overlap of ALS and FTD. Attached from Ling et al. [17]. 
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1.1.2 Clinical diagnosis 
The diagnosis of ALS is based on clinical features, electrodiagnostic 
testing, and exclusion of other pathological conditions with related 
symptoms. The El Escorial criteria (EEC), first defined by the World 
Federation of Neurology in 1993 and then revised in 1998, are the most-
commonly used guidelines for the diagnosis of ALS world-wide [23,24]. 
The diagnosis of ALS requires the presence of UMN and LMN signs in 
different anatomical segments (bulbar, cervical, thoraco-abdominal and 
lumbosacral) at neurological examination [8].  
Additionally, appropriate neurophysiological and neuroradiological 
investigations play an important role in supporting the clinical diagnosis. 
Electrophysiological studies include: a) electromyography (EMG) to detect 
signs of muscle denervation, and provide evidence of LMNs dysfunction;  
b) nerve conduction studies (NCS) aimed to exclude other mimic 
conditions, such as peripheral neuropathy or  myopathy [8]; c) transcranial 
magnetic stimulation producing motor evoked potentials (TMS-MEPs) to 
detect signs of UMN dysfunction. Neuroradiological investigations of brain 
and spinal cord are executed to exclude other conditions, like structural 
lesions, that might cause the same clinical signs, while in some instances 
muscle biopsy can be performed to reveal denervation atrophy and to 
exclude the suspect of a myopathy. Genetic testing for mutations in ALS 
causative genes can be additionally requested in familial cases to confirm a 
suspected genetic condition. 
The spreading of symptoms or signs within a region or to other regions, 
attested thorough periodic medical examinations, is necessary to 
demonstrate the disease progression, compatible with a neurodegenerative 
process. 
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The revised EEC classify  ALS  in different categories, according to the 
number of body regions clinically affected [24]:  
 Clinically definite ALS : both LMN and UMN signs in at least 3 body 
regions 
 Clinically probable ALS: both LMN and UMN signs in at least 2 body 
regions 
 Clinically probable – laboratory supported ALS: LMN and UMN 
signs in 1 body region only, associated to electromyographic signs 
of active and chronic degeneration in at least 2 extremities 
 Possible ALS: signs of LMN and UMN in 1 body region only or UMN 
signs in 2 or more body regions 
 
To assess the cognitive status of ALS patients, clinicians apply particular 
neuropsychological tests to investigate a range of different cognitive 
disturbances,  minimizing the limitations imposed by dysarthria, hand 
weakness and other motor disabilities in ALS. In the last years, a 
specifically implemented cognitive test,  called Edinburgh Cognitive and 
Behavioural ALS Screen (ECAS), has been developed to determine the 
presence, severity and type of cognitive and/or behavioural changes in ALS 
patients [25]. This test results particularly sensitive as investigates different 
domains: executive functions, fluency, language (maming, comprehension, 
spelling), memory and visuospatial functions. 
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1.1.3  Etiology of ALS  
ALS occurs prevalently as a sporadic form (SALS), a complex condition 
determined by the interplay of genetic and environmental risk factors. The 
role of a significant genetic component is supported by twin pairs studies 
that estimated the heritability of sporadic ALS at 0.61 [26]. In addition, a 
small but definite increased risk for ALS was found among first-degree 
relatives of patients [27]. Age and gender are recognized as non genetic 
ALS risk factors: older age is positively associated with the risk of 
developing ALS, and men are slightly more likely to develop ALS than 
women. Environmental factors that have been associated with ALS risk 
include cigarette smoking, exposure to heavy metals and pesticides, 
intensive physical activity and head injuries [28]. 
Only a small proportion of cases (5-10%) reports a positive family history 
and is classified as familial form (FALS) [29]. FALS cases are clinically 
indistinguishable from SALS,  but generally they are characterized by an 
equal male:female sex ratio, an earlier age at onset (47.5 years in FALS vs 
56 years in SALS), and a longer disease duration [30].  
A systematic review of published epidemiological studies show a 
geographical difference in incidence of FALS, with a higher value in Finland 
and lower rates in populations of Southern Italy and of the Balkan 
Peninsula [29]. Generally, an ALS case is considered familial if at least 
another family member (within four-degree relative) is affected by the same 
condition. Considering the absence of a definitive consensus on FALS 
definition, recently Byrne et al. [31] proposed novel consensus criteria that 
classify FALS forms in three categories according to family history: a) 
“definite FALS” for pedigrees with three or more affected members; b) 
“probable FALS” if another first- or second- degree relative suffers of the 
same condition; c) “possible FALS” if the other affected member is a distant 
relative.  
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Families with ALS frequently show an autosomal dominant transmission 
pattern, although autosomal recessive and X-linked pedigrees are also 
described [32]. To date, more than 20 genes explaining the 60% of familial 
forms have been identified, enlighting the great genetic heterogeneity 
underlying the disease [33].  
 
1.1.4 Role of enviromental risk factors 
Many epidemiological studied were conducted to assess the potential 
involvement of enviromental factors in the development of sporadic forms 
and a growing list of potential risk factors was proposed. 
A strong role of environmental factors in ALS disease pathogenesis was 
first supposed by studying Western Pacific endemic foci, where in 1960s 
local populations showed an extremely high incidence rate of ALS and 
ALS-related syndromes [5]. The most reliable hypothesis suggests that 
ALS was induced by a particular chronic dietary consumption of 
cyanobacterial toxin β-methylamino-L-alanine (BMAA) contained in cycad 
plants and biomagnified in flying foxes [34]. BMAA was, in fact, detected in 
brain tissue of ALS-affected individiduals of Chamorro population in Guam, 
and this compound has proven to induce neuronal cell death in different 
animal models, including primates [35]. Moreover, in these geographical 
areas with an unusually high incidence of ALS, analysis of soil and drinking 
water revealed high levels of mineral content, prevalently aluminum and 
manganese [36]. The role of such modifiable environmental risk factors is 
confirmed by a drastic decrease of ALS incidence in Guam over the past 30 
years (from 70/100,000 in 1960s to 7/100,000 in 1990s), in association with 
radical changes in  socio-economic conditions, dietary habits and  life-style 
[36].  Interestingly, ALS clusters have been identified also in other 
geographical regions which are subject to frequent ‘‘blooms’’ of 
cyanobacteria, including the area near Lake Mascoma in New Hampshire 
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and the Hérault district surrounding Thau lagoon in Southern France 
[37,38].  
Exposure to chemical neurotoxins (organophosphates) has also been 
hypothesized to explain the increased risk for ALS reported in certain 
occupational categories, like agricultural workers and veterans of the 1990-
1991 Gulf  War, for whom a higher exposure to these compounds is 
expected [28]. Organophosphates, commonly  found in a wide variety of 
insecticide preparations for agricultural use and present also in nerve 
agents (e.g. sarin and cyclosarin), act by inhibiting the action of 
acetylcholinesterase (AChE) in nerve cells.  
Together with agricultural pesticides,  heavy metals, such as mercury and 
lead, are the most likely toxicants routinely encountered by humans, being  
present in air, water, soil and multiple dietary sources. Therefore, the 
potential pathogenic role of heavy metals in triggering neurodegeneration 
has received considerable attention. Different approaches have been taken 
to study metal toxicity in ALS, including the measurement of metal levels in 
patients’ body tissues or fluids and the evaluation of ALS-related clinical 
symptoms in individuals subjected to heavy metal exposure. Individuals 
exposed to high doses of mercury and lead display numerous neurological 
abnormalities, including motor signs resembling ALS, such as  extremity 
weakness, spasticity, hyperreflexia, fasciculation and ataxia [39]. Also 
animal studies seem to suggest a role of mercury in disease development, 
as indicated by the observation that a single dose of mercuric chloride 
(HgCl2) in mice can cause deposition of mercury in upper and lower motor 
neurons [40]. Moreover, mouse models of ALS (transgenic mice SOD1 
G93A) treated with methylmercury show an earlier onset of hind limb 
weakness [40]. However, a cause and effect relationship between exposure 
to mercury and ALS has never been specifically demonstrated.   
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Additional studies focused on different metals, including selenium, copper 
and zinc, aluminum and cadmium, but they failed to produce reliable and 
robust results [41]. 
Other associations have been postulated with intense physical activity, 
head injury, viral infections, cigarette smoking, electromagnetic fields (EMF) 
and electrical shocks [28]. The involvement of physical activity as a risk 
factor has been first hypothesized after that the legendary baseball player 
Lou Gehrig died from ALS in 1930’s and has been recently reinforced  by 
the report of a higher than expected incidence of the disease in 
professional soccer and football players [42]. However, evidence from 
epidemiological research remains conflicting and inconclusive. Persistent 
viral infections have been suggested as a predisposing factor for the 
development of ALS, after finding enterovirus sequences in a consistent 
group of spinal cord samples from ALS patients. Some retroviral infections 
(HIV and HTLV-1) have also been described in association with ALS-like 
syndromes [43].  
Although there is a compelling evidence of the role of environment in ALS 
susceptibility, the lack of a robust evidence underline the importance of 
novel studies on larger cohort of individuals to elucidate the direct 
involvement of exogenous factors in ALS etiology. More recently, the 
involvement of epigenetic mechanisms (DNA methylation and histone 
acetylation) has been investigated in an increasing number of 
neurodegenerative diseases. It’s believed that epigenetic changes on the 
genome may be a mechanism through which environment can contribute to 
the pathophysiology of age-related neurodegenerative disorders.         
An increase in global methylation was observed  in postmortem SALS 
spinal cord, probably reflecting the significant abnormalities of  methylation 
regulators such as the DNMTs (Dnmt1, Dnmt3a) detected in motor neurons 
[44].   
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1.2 Genetics of ALS 
The genetics of ALS is very complex, characterized by the involvement of 
major causative genes which underly familial cases and a small fraction of 
SALS cases, and by susceptibility factors contributing to the etiology of the 
sporadic forms in association with other low penetrant genetic variants 
and/or with environmental risk factors [28]. Over the past decade the 
research in ALS genetics has been extremely productive: it provided 
fundamental insights into the pathogenesis of the disease unraveling the 
involvement of multiple and different biological process mediating 
neurodegeneration and facilitating disease modeling useful for therapeutic 
testing.  
1.2.1  Causative  genes  
To date, genetic studies have identified more than 20 major genes, whose 
mutations cause familial forms of ALS (Table 1). These causative genes 
have a  key role in the pathogenesis of the disease, being able to induce 
ALS with a monogenic Mendelian pattern of  inheritance. Both autosomal 
dominant (SOD1, c9orf72, FUS/TLS, TARDBP, VAPB, OPTN, VCP, DAO, 
SETX, hnRNPA2B1/A1), autosomal recessive (ALS2, SPG11, OPTN) and 
X-linked (UBQLN2) forms of ALS have been reported [45]. Thanks to the 
advent of next-generation sequencing which led to the identification of 
novel disease causative genes in the last years,  now the genetic cause is 
known for about 60% of FALS. Notably, mutations in major genes 
associated to FALS have been also identified in patients with apparently 
sporadic ALS. Some of these patients may be FALS misdiagnosed as 
SALS for the lack of complete information about other family members. 
Other mechanisms explaining this finding are incomplete penetrance of the 
mutations or  the occurrence of de novo mutations. 
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Although the great genetic heterogeneity reported in ALS, the major genetic 
contributors to FALS are SOD1, c9orf72, TARDBP and FUS, which globally 
account for almost 50% of familial and 10% of sporadic forms[45]. For 
these genes, that have been extensively characterized through large-scale 
epidemiological studies and supported by functional studies, an accurate 
understanding in terms of mutational frequency, penetrance and genotype-
phenotype correlation is available.   
SOD1 
SOD1 was the first gene to be identified in 1993, based on linkage analysis 
in autosomal dominant  FALS pedigrees [46]. The gene encode for the 
Cu/Zn superoxide dismutase, a cytoplasmic enzyme responsible for the 
catabolism of superoxide radicals to hydrogen peroxide and molecular 
oxygen.  More than 140 different SOD1 mutations, collectively accounting 
for  ~20% of all FALS patients and in ~3% of SALS cases, have been 
identified in all the five exons of the gene. All SOD1 mutations are inherited 
as dominant traits, with the exception of the D90A variant, that is observed 
both in recessive pedigrees in Scandinavia, and in dominant pedigrees in 
the rest of the world [47]. SOD1 mutations are characterized by a 
considerable interfamilial and intrafamilial phenotypic variability with 
regards to the age at onset, site of onset, and disease duration. The  A4V 
mutation, the most frequent in North America,  is consistently associated 
with a high penetrance, younger age at onset, prevalence of lower motor 
neuron signs, and a short survival with death occurring usually  within 12 
months.  Conversely, other mutations, such as G41D, H46R and G93D, 
may display a very mild phenotype, with carriers often surviving more than 
20 years after disease onset [47]. 
The identification of SOD1 was a major breakout in ALS because in the 
following years the development and the extensive study of different mutant 
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SOD1 transgenic mice were fundamental to investigate the pathogenic 
mechanisms and pathways involved in motor neuron (MN) degeneration.   
 
C9ORF72 
A hexanucleotide intronic repeat expansion within C9orf72 gene was 
identified recently as the most common genetic cause of familial and 
sporadic ALS and FTD [19-20]. The repeat (GGGGCC) is highly 
polymorphic in the normal population (2–23 units), but is massively 
expanded in patients (up to 4000 units).  Mutational frequency varies 
between different populations and countries, ranging from 23%–47% in 
FALS and  4%–8% in SALS in Western populations [46]. Within Europe, 
the highest mutation frequency is observed in Finland (46.4% of FALS and 
21.1% of SALS), probably a condition determined by the combination of 
two genetic phenomena (the founder effect and genetic drift) [48]. The 
contribution of C9orf72 gene to ALS results significantly lower in non 
European populations:  the repeat expansion was found to account for 
2.8% of familial ALS and 0.4% of sporadic ALS in Japanese population [49] 
and similar low mutational frequencies were observed also in Iran [50].          
ALS patients with C9orf72 repeat expansions are characterized by a 
preferential bulbar onset, a shorter survival time, concurrence of cognitive 
impairment and involvement of extra-motor neuronal structures. The finding 
that individuals with concurrent ALS and FTLD or with a family history of 
dementia or motor neuron disease have a higher risk of harboring C9orf72 
repeat expansions (33-86%) further support that recognition the two 
diseases belong to the same pathogenic continuum [51].  
The exact cellular functions of C9ORF72, expressed in many tissues, 
including cerebellum, cortex and spinal cord, remains undefined but a  
recent study demonstrated that C9ORF72 regulates intracellular trafficking 
processes in the endosomal and autophagy-lysosomal compartments [52]. 
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TARDBP  
The TARDBP gene  was identified as ALS causative gene in 2008 [53], 
after the discovery that the gene product, 43-kDa TAR-DNA binding protein 
(TDP-43) , was a  major constituent of ubiquitinated cytoplasmic inclusions 
in ALS affected motor neurons [21]. TDP-43 is a DNA/RNA binding protein 
belonging involved in different processes of RNA metabolism, including 
gene transcription, splicing regulation, and transport and stabilization of 
mRNA molecules [54]. To date, a total of 47 missense variants and one 
deletion/insertion have been identified in ALS cases: the current prevalence 
of these mutations is ∼5% of FALS and ∼1.5% of SALS cases, with notable 
differences between different geographical regions [55]. The penetrance of 
TARDBP mutations is believed to be incomplete, with several carriers not 
developing ALS even in their advanced age. Rarely, patients carrying 
TARDBP mutations can present signs of cognitive impairment, FTD or 
parkinsonism. With a single exception (the p.D169G mutation), the rest of 
the pathogenic mutations identified so far are located in the C-terminal 
glycine-rich region encoded by exon 6 [55]. The p.A382T variant, initially 
identified in two French cases, is the most commonly observed in patients. 
This variant, which is also associated to parkinsonisms, displays a high 
mutational frequency in Sardinia (20-30%) possibly due to a founder effect  
[56].  
FUS 
Mutations in FUS were identified in 2009 by two different research groups 
in ALS families with a previously identified linkage on a locus in 
chromosome16 (ALS6) [57-59]. The FUS gene, comprising 15 exons, 
encodes for a DNA/RNA binding protein normally localized in the cell 
nucleus, which  plays a similar role to TDP-43 in transcriptional regulation, 
RNA splicing,  nucleo-cytoplasmic RNA shuttling, and maturation of 
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mRNAs [54]. So far, 58 mutations have been identified with a mutational 
frequency of approximaly 4-5% in FALS and 1% in SALS [55]. The vast 
majority of FUS mutations are missense substitutions, but also splicing, 
frameshit and non-sense mutations have been reported. Similarly to 
TARDBP, most of the ALS-linked variants of FUS are clustered in the C-
terminal region, which contains the nuclear localization signal (NLS) of the 
protein [54]. Further, FUS mutations have been often associated with a 
juvenile onset highly aggressive type of ALS. 
Mutations in other genes associated with FALS have been reported in 
isolated families and  collectively account for a small proportions of cases 
(less than~5%) [45].   The genetic cause is still unknown for the remaing 
40% of FALS cases.  
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Table 1. Causative ALS genes 
 Causative genes  Inheritance 
Estimated % 
of FALS 
Enzyme 
 Superoxide dismutase 1 (SOD1) Dominant 20% 
RNA metabolism 
 TAR DNA-binding protein 43 (TARDBP) Dominant 1-5% 
 Fused in Sarcoma (FUS) Dominant 1-5% 
 TATA-binding protein associated factor 15 (TAF15) Unknown Unknown 
 Ewing Sarcoma breakpoint region 1 (EWSR1) Unknown Unknown 
 Angiogenin (ANG) Dominant <1% 
 Senataxin (SETX) Dominant Unknown 
 Matrin 3 (MATR3) Dominant Unknown  
Repeat Expansions 
 C9ORF72 Dominant 22-65% 
 Ataxin 2 (ATXN2) Dominant <1% 
Proteostatic proteins 
 Ubiquilin 2 (UBQLN2) Dominant <1% 
 Optineurin  (OPTN) Dominant <1% 
 Sequestosome (SQSTM1) Dominant Unknown 
 Valosin-containing protein (VCP) Dominant <1% 
CHMP2B Dominant Unknown 
 Phosphatidylinositol 3,5-biphosphate 5-     
phosphatase (FIG4) 
Dominant Unknown 
Excitotoxicity 
 D-amino-acid oxidase (DAO) Dominant <1% 
Cytoskeleton/cellular tran sport deficits 
 Vescicle-associated membrane protein B ( VAPB) Dominant <1% 
 Peripherin (PRPH) Sporadic Unknown 
 Dynactin 1 (DCTN1) Dominant Unknown 
 Neurofilament heavy chain (NFH) Dominant Unknown 
 Profilin 1 (PFN1) Dominant Unknown 
Uncertain 
 Spatacsin Recessive Unknown 
 Alsin (ALS2) Recessive <1% 
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1.2.2 Genetic risk factors 
The great majority of SALS cases are thought to result from the complex 
interplay between environmental factors and “susceptibility genes”, each 
one of them increasing the individual’s predisposition to ALS with an 
additive effect.  Many predisposing genes have been identified so far by 
using candidate association case-controls studies but often the 
associations were not replicated in other studies.  
Among the genes implicated in the etiopathogenesis of sporadic ALS there 
are ANG and VEGF, which  encode for proteins involved in the formation of 
new blood vessels (a process known as angiogenesis) but increasingly 
recognized to act as neurotrophic molecules regulating neurogenesis, 
neuronal survival and migration [60]. Several lines of evidence, functional 
and genetic, have associated these genes to ALS. Knockout mice for the 
hypoxia-response element (HRE) of the vascular endothelial growth factor 
(VEGF) promoter develop an adult-onset progressive motor neuron 
degeneration resembling ALS. Moreover the intracerebroventricular 
delivery of recombinant VEGF in SOD1G93A rat model delays onset of 
paralysis by 17 days, improves motor performance and prolongs survival by 
22 days [61]. In humans the single nucleotide polymorphism (SNPs)  -
2578C/A in the upstream promoter region of VEGF,  resulting in a lower 
level of  gene expression, has been confirmed by a recent metanalysis to 
be correlated with an increased susceptibility to ALS in males [62]. Also for 
the other angiogenic gene, ANG, a significant higher frequency of variants 
has been demonstrated  in ALS patients compared to control subjects (p = 
9.3 × 10-6) [63].  
Many other studies focused on environmental response genes, like PON 
(paraoxonase)  and HFE, with the aim to find genetic support to the 
epidemiological evidences of  the role of toxin exposure in ALS 
pathogenesis. 
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The paraoxonase gene family is a cluster constituted of three 3 genes 
(PON1, PON2, PON3) located in a region spanning ~140 kb on 
chromosome 7q21.3-q22.1. Their involvement in ALS pathogenesis has 
been investigated because all three PON proteins share lipid antioxidant 
properties and moreover, PON1 is implicated in detoxifying neurotoxic 
organophosphate compounds [64]. A 5-SNPs haplotype in the PON1 
promoter region was found to be significantly associated with risk of 
sporadic ALS (p=2.42E-04) and 7 missense mutations in the coding region 
of PON1, predicted to alter protein function, have been identified in FALS 
and SALS cases but not in controls [64,65]. 
HFE gene encodes for a membrane protein regulating the iron 
homeostasis, which play an important role in many biological processes. 
Given that both iron overload and iron depletion cause neuronal 
dysfunction, variations in HFE gene have been recently investigated as 
potential genetic risk factors for ALS and for other neurodegenerative 
disorders such as Parkinson’s disease (PD) [66]. The variant H63D was 
observed at higher frequency in SALS cases compared to controls in 
different genetic reports and a recent meta-analysis considering 66,000 
cases confirmed that homozygosity for this variant is associated with a 4-
fold risk of developing ALS [66].   
More recently, intermediate CAG repeats (30-33) in the ATXN2 gene, 
cause of  spinocerebellar ataxia type 2 (SCA2),  have  been associated 
with a significant increased risk of ALS (odds ratio (OR) = 4.44) in 
Caucasian ALS patients [67]. 
In the last  years,  genome-wide association studies  (GWAs) were applied  
to identify ALS susceptibility genes in a unbiased manner, but the 
involvement of multiple loci with an additive effects (polygenic threshold 
model)  complicates the analysis of genetic components contributing to 
sporadic forms. 
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1.2.3.  Methodologies used to identify ALS genes 
 1.2.3.1 Linkage analysis 
Many ALS pedigrees show a Mendelian pattern of inheritance (mostly 
autosomal dominant) and therefore can be studied by linkage analysis to 
map and identify disease-causing genes. Linkage analysis is based on the 
identification of genetic markers that are co-inherited with the disease and 
is a powerful method to map disease loci. In the past, researchers used as 
informative DNA markers Short Tandem Repeat (STRs) or Variable 
Number Tandem Repeats (VNTRs). Today the analysis is based on SNPs 
that, although less polymorphic, are more abundant and can be 
simultaneously tested in automated high-throughput genotyping arrays.     
A main advantage of linkage analysis is that it is unbiased and genome-
wide, and does not require a prior knowledge of the pathogenic 
mechanisms underlying the disease. Family-based studies, supported by 
linkage analysis, have been the starting point for the identification of 
different ALS genes. In 1989 the first locus (ALS1) associated with 
dominant  ALS was identified to be on chromosome 21q22.1 by linkage 
analysis in 6 multigenerational ALS families [68]. The maximum lod score 
was obtained for the marker D21S223 localized within exon 2 of SOD1. 
Subsequently, 11 different  SOD1 missense mutations were identified in 
affected members of 13 familial ALS pedigrees by single-strand 
conformational polymorphism analysis and direct sequencing of exons [44].  
Following this first success, classical linkage studies have led to the 
discovery of 10 new ALS loci, including loci responsible for recessive forms 
of ALS, such as ALS2  (chromosome 2q33),  caused by mutations in the 
Alsin gene, and ALS5  (chromosome 15q15-21)  caused by mutations in 
Spatacsin gene  [47]. 
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1.2.3.2  Candidate gene approach 
The discovery of neuropathological features and pathomechanisms of ALS 
pointed researchers towards investigating suitable “candidate genes” 
potentially playing an important role in disease pathogenesis. This 
approach was successful in identifying TARDBP, one of the most common 
causative genes in ALS. Following the discovery of TDP-43 as a major 
component of ubiquitinated inclusions in affected motor neurons [18], three 
different groups screened the entire coding region of TARDBP gene in a 
large cohort of ALS patients and identified different missense mutations 
[53,55]. Following these studies, an increasing  number of reports on ALS 
patients of different geographic origin were published and effectively 
TARDBP mutations were found to be a major cause of FALS and also of a 
small fractions of sporadic cases [55].  
Similarly, the genes NEFH, encoding for the neurofilament  heavy subunit, 
and PRPH, encoding for peripherin, were also analyzed as candidate 
genes because of an abnormal accumulation of intermediate filaments in 
the perikarya and proximal axons of motor neurons in ALS patients [69]. Six 
deletions within the C-terminal lysine-serine-proline (KSP) phosphorylation 
domain of the NEFH gene were found in several SALS patients and in a 
pedigree with autosomal dominant FALS, while an homozygous missense 
mutation and a heterozygous frameshift deletion of the PRPH gene were 
observed in ALS cases [47].  
Finally, other studies selected candidate genes for genetic screening 
because of structural and functional similarity to known ALS-genes: one 
example is represented by TAF15 and EWS which together with FUS 
belong to the FET family of RNA-binding proteins and are implicated in 
regulation of gene expression, maintenance of genomic integrity and 
mRNA/microRNA processing [70]. 
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1.2.3.3  Genome-wide association studies 
One of the most used approach to identify susceptibility genes in sporadic 
ALS is represented by genome-wide association (GWA) studies. Unlike 
candidate-gene approaches, genome-wide association (GWA) study is a 
non-hypothesis-driven method which analyzes the entire genome (genic 
and intergenic regions) to find loci associated to the disease. Basically, 
GWA studies are case-control studies that, using data obtained by high 
throughput genotyping platforms, compare allelic frequencies of many 
common SNPs (300.000-600.000) across the human genome between 
affected individuals and healthy controls. The result of a GWA study is the 
identification of SNPs associated to the disease, either because they have 
a direct causative role in the pathogenesis of the condition (coding variants 
affecting protein function or variants affecting transcription and translation) 
or because they are in linkage disequilibrium with the actual causal variant. 
Over the last years, many GWA studies have been performed in large 
SALS cohorts, identifying several loci associated with disease risk, such as 
DPP6 (dipeptidyl peptidase 6), ITPR2 (inositol 1,4,5-triphosphate 
receptortype 2), ELP3 (the elongator protein 3), SUNC1, chromosome 
9p21, UNC13a [45]. Unfortunately, with the exception of the signal on 
chromosome 9p21, the other genetic associations failed to be robustly 
replicated in independent studies [71]. The 9p21 locus associated to 
sporadic ALS overlapped with a 3∙6 Mb region previousily linked to ALS-
FTD in seven families [72]: only after an extensive search,  the genetic 
cause of chromosome 9-linked FTLD-ALS was identified in the non-coding 
hexanucleotide  repeat expansion within the gene C9ORF72 [20,21]. This 
finding has underlined the critical importance of very large sample sizes in 
order to have sufficient power to capture allelic association with small 
effects and low MAF. Recently, by performing a meta-analytical GWAS 
study on a total of 13,225 individuals (6,100 cases and 7,125 controls) for 
25 
 
almost 7 million SNPs, our research group confirmed the previously 
reported association at 9p21 with the expanded hexanucleotide repeat in 
the C9orf72 gene (rs3849943 with P = 7.69 x 10-9; OR 1.16) and identified 
a novel  locus for sporadic ALS risk at 17q11.2 (rs34517613 P = 1.11 x 10-
8; OR 0.82) that was validated  using genotype data from a replication 
cohort [73]. The lead SNP at this locus was in linkage with three SNPs in 
the SARM1 gene,  which seem to promote an axonal self-destruction 
pathway known as Wallerian degeneration. 
Additionally, GWAs have been also used to identify modifier genes, that not 
increase the risk of developing ALS but modulate penetrance, age of onset, 
rate of progression, survival. One example of disease modifier is KIFAP3, a 
gene encoding for a kinesin associated protein involved in cellular 
anterograde transport and chromosomal cytokinesis. A genome-wide 
analysis in 1,821 sporadic ALS cases and 2,258 controls revealed that the  
SNP rs1541160  within the KIFAP3 gene  is associated with reduced 
KIFAP3 expression and longer survival. The homozygous genotype C/C of 
the SNP rs1541160 increase the mean survival of ≈14 months, a variation 
of clinical importance for a rapidly progressive disorder like ALS 
characterized by  a survival of only 3–5 years [74].  
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1.2.3.4  Whole-exome sequencing 
Until recently, it was not feasible to perform genome-wide sequencing on 
large cohorts. However, the recent advances in automated short-read DNA 
sequencing technologies have rendered the whole genome sequencing 
and in particular the target sequencing of the exome a powerful and cost-
effective tool for genetic studies. The exome (the protein-coding regions of 
the genome) constitutes only approximately 1% of the human genome, but 
harbours about 85% of the mutations responsible for Mendelian disorders. 
Ever since the first application in Miller syndrome, whole-exome 
sequencing (WES) has proven to be highly successful in discovering the 
genetic bases of several rare Mendelian disorders in which conventional 
approaches have failed [75]. To date WES has proven to be useful also in 
ALS with the identification of different causative genes (Figure 3). This 
approach was successful also in small pedigrees, where a limited number 
of patients was sequenced. For example, the VCP gene, previousily 
associated to Inclusion Body Myopathy, Paget disease, and Frontotemporal 
Dementia (IBMPFD), was identified as an ALS causative gene by 
performing exome-sequencing on only two affected members of a four-
generation Italian ALS family [76]. By applying a similar approach, a 
mutation in the hnRNPA2B1 (heterogeneous nuclear ribonucleoprotein 
A2B1) gene was identified in one family with IBMPFD/ALS, and two 
mutations in hnRNPA1 (heterogeneous nuclear ribonucleoprotein A1) gene 
were found in two families with pure ALS [77] More recently, the exome-
sequencing approach has been applied also to sporadic ALS in a “trios” 
study design (one affected proband and the two unaffected parents) to 
identify potential de novo mutations. This study analyzed 47 ALS trios and 
reported a significant enrichment of de novo mutations in genes encoding 
for proteins belonging to the chromatin regulatory pathway [78]. 
 
27 
 
Figure 3. Timeline of gene discoveries in familial and sporadic ALS. 
The exponential growth in genetics related to ALS after the application of 
exome-sequencing approach. Attached from Renton et al. [79]. 
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1.2.4 Problems and limitations in the study of ALS genetics 
The information provided by genetic studies toward the understanding of 
ALS pathogenesis has been invaluable. It has led over the years to the 
identification of multiple and different biological process involved in motor 
neuron degeneration, has provided potential therapeutic targets, and 
facilitated the engineering of ALS animal models, essential for validating 
drugs efficacy [1]. Although the great advances achieved over the last 
decades, only 50-60% of the genetic variability in FALS has been explained 
so far, while the genetic component of sporadic forms is even less 
understood. This is explained in part by the complex genetic heterogeneity 
underlying ALS and by the limited success achieved by traditional genetic 
approaches, such as the linkage analysis and the candidate gene 
approach. Linkage analysis requires the study of large pedigrees 
composed of many affected individuals in different generations. This task is 
considerably difficult in ALS, that occurs in adult life and has a rapid 
disease course. Many FALS pedigrees collected for research purpose are 
not large enough to effectively map the disease gene with the linkage 
approach. Moreover, similarly to other complex neurodegenerative 
diseases, the analysis of  FALS pedigrees  is complicated by a variable age 
of onset, incomplete penetrance and phenotypic heterogeneity. 
Misdiagnosis of ALS in family members and pleiotropy of implicated genes 
can be other sources of error [45]. The candidate approach, which has the 
advantage to be feasible in cohorts of unrelated FALS and in SALS, is 
flawed by a selection bias and the several studies conducted so far have 
been inconsistent and frequently underpowered. Many GWAs studies, 
aimed at identifying susceptibility genes in SALS, were not able to produce 
convincing and replicable results. Moreover, odds ratios associated with 
putative risk alleles identified so far are generally low, indicating a modest 
risk effect and the probable involvement of many susceptibility genes that 
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cumulatively elevate the risk of developing ALS. The common variants 
interrogated by SNPs genotyping chip in GWAs studies seem typically to 
explain only a small fraction (12-21%) of the calculated inherited 
contribution to ALS risk [66]. Therefore, it’s been proposed that low-
frequency or rare variants, not captured by the SNPs arrays used for GWAs 
but with presumably higher effect sizes, may account for the “missing 
heritability” in SALS. New approaches (such as genome-wide and exome 
sequencing) are thus required to define more comprehensively the 
inherited basis of the disease both for FALS and SALS. Next-generation 
sequencing and in particular WES have proved to be a successful and 
efficient method for the study of genetics in neurodegenerative disorders, 
including ALS.  Using this technology researchers have been able to 
identify causative genes in familial pedigrees analyzing a limited number of 
affected members and more recently applying a trio–based approach,  
investigated the contribution of de novo mutations to disease susceptibility.  
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1.3 Pathogenic mechanisms 
While the exact molecular and cellular basis for motor neuron degeneration 
is not yet fully understood, increasing evidence point to the contribution of  
multiple aberrant biological processes. The cellular events contributing to 
the pathobiology of ALS include protein aggregation, dysregulated RNA 
metabolism, oxidative stress, mitochondrial dysfunction, excitotoxicity, 
impaired axonal transport and neuroinflammation (Figure 4).  
1.3. 1 Protein aggregation  
Similarly to other neurodegenerative disease (Alzheimer’s, Parkinson’s and 
Huntington’s diseases), misfolding and protein aggregation seem to be 
crucial also in ALS pathogenesis.   The presence of ubiquitinated inclusions 
in LMNs of the spinal cord and brainstem and in corticospinal UMNs is the 
pathological hallmark of ALS. Using a combined biochemical and 
immunoistochemical approach, TDP-43 was identified as the main 
component of ubiquitinated cytoplasmic inclusions in ALS and in a sub-
population of Frontotemporal lobar dementia with ubiquitin inclusions 
(FTLD-U) patients [18].  In aggregates, TDP-43 is hyperphosphorylated and 
cleaved to generate abnormal C-terminal fragments. Since in ALS affected 
motor neurons TDP-43 is mislocalized in the cytoplasm forming intracellular 
aggregates, its altered localization may play a pivotal role in 
neurodegeneration resulting in the loss of their proper function in the 
nucleus (loss-of-function effects) and/or in their potential toxicity in the 
cytoplasm (gain-of-function effects) [54]. Misfolding and aggregation is a 
propensity demonstrated also for other ALS-linked proteins, including FUS, 
SOD1, OPTN, UBQLN2,  HNRNPA2/B1, VCP and the poly-(glycine-
proline) peptides generated by repeat associated non-ATG translation 
(RAN translation) of the C9ORF72 repeat transcripts [1].  Cytoplasmatic 
inclusion immunoreactive for FUS have been found in disease affected 
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tissues from patients harboring FUS mutations [80] but , in contrast to TDP-
43, there are no evidence of the presence of  hyperphosphorylated or 
cleaved forms of FUS protein in the aggregates. Interestingly, both TDP-43 
and FUS contain 'prion-related' glutamine/asparagine (Q/N) rich domains 
that could induce protein aggregation [81]: a similar domain is present in 
two other RNA-binding protein, hnRNPA2/B1 and hnRNPA1, found to be 
mutated and aggregated in ALS [77]. SOD1 is a primary component of 
protein aggregates found in SOD1-mutated FALS patients and in mutant 
SOD1 rodent disease models. According to in silico and experimental 
studies,  ALS SOD1 variants show an increased propensity to form 
aggregates, due to dimer destabilization and dissociation into monomers 
which then nucleate the formation of aggregates.  Protein instability and 
aggregation propensity are two factor correlating with the disease severity  
in SOD1+ FALS patients [82]. 
1.3.2  RNA metabolism  
Abberant RNA has been described in many neurodegenerative diseases 
and seems to be of major importance also in ALS pathogenesis. TDP-43 
and FUS are two RNA-binding proteins involved in multiple steps of RNA 
processing pathway, from transcription to post-transcriptional regulatory 
process (splicing, mRNA stabilization and transport). The altered 
localization of these two proteins forming cytoplasmic inclusions in affected 
tissue determines a sequestration and loss of their normal nuclear function 
with possible severe consequences on mRNA metabolism and therefore on 
the survival of motor neurons. 
The role played by altered RNA homeostasis in ALS pathogenesis is further 
emphasized by the evidence that several mutations observed in patients 
affect other RNA-processing genes, including hnRNPA2/B1, optineurin 
(OPTN),  senataxin (SETX), angiogenin (ANG), elongator protein 3 (Elp3) 
and survival motor neuron (SMN) [54]. The recent finding that sense and 
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anti-sense transcripts of the expanded repeat in C9orf72 accumulate in 
nuclear RNA foci, sequestering several RNA-binding proteins, has further 
supported the central role of RNA dysregulation in ALS [83]. 
1.3.3 Mitochondrial dysfunction  
Several experimental evidences support the notion that alterations in 
mitochondrial morphology, bioenergetics and fusion/fission dynamics play 
an important role in ALS [84]. Morphological alterations, such as 
fragmentation, and changes in mitochondrial function, like a reduction in the 
activity of respiratory chain complexes and decline of mitochondrial 
bioenergetic capacity, have been reported  in ALS patients, in cultured cells 
expressing mutant SOD1 and in mutant SOD1 transgenic mice. Although a 
cytosolic protein, a fraction of SOD1 (1-2%) is translocated into the 
mitochondrial intermembrane space (IMS) with the function to protect the 
cell from additional oxidative stress damage by oxygen radicals. An 
increased mitochondrial recruitment and accumulation have been observed 
for mutant SOD1: mitochondrial mutSOD1 may directly damage these 
organelles by forming toxic aggregates or by engaging abnormal 
interactions with other mitochondrial proteins, like Bcl-2  [52]. 
1.3.4 Cytoskeletal abnormalities 
Different cytoskeletal abnormalities have been reported in ALS cases, 
including abnormal accumulation of intermediate filaments (IF) in the 
perikaryon and axons of motor neurons. Neurofilaments (NFs) are the 
major type of IFs in adult motor neurons and are formed by three proteins,  
NF light (NF-L), NF medium (NF-M) and NF heavy (NF-H). Genetic defects 
in the NF-H gene have been identified in a small number of patients, 
providing compelling evidence for involvement of cytoskeletal defects in 
ALS. Significant loss of motor axons (20 to 25%) has been reported in NF-L 
null mice and in mice knockout for both NF-M and NF-H [85], while the 
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overexpression of any of the three NF subunits in mice induced the 
formation of perikaryal NF accumulations reminiscent of those found in 
human ALS. Another type of IF detected in the abnormal inclusion in ALS 
motor neurons is peripherin. Notably, the expression of peripherin can be 
upregulated by imflammatory cytokines, such as IL-6, which was found to 
be increased in the cerebrospinal fluid of ALS patients.  
Other potential mechanisms of toxicity targeting motor neurons defects in 
axonal transport, glial cell pathology, and glutamate excitotoxicity, although 
the primary or secondary role of each of these events in triggering MN 
degeneration still need to be determined [84]. 
Figure 4.  Pathogenic mechanisms in ALS.  Attached from Robberecht et 
al. [84] 
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2. AIM OF THE PROJECT 
Despite numerous advances over the last few years, the genetic basis of 
~40% of familial ALS remains to be identified, while the genetic causes of 
sporadic ALS are even less understood. Continuous efforts are needed to 
identify the missing heritability and to increase our understanding of the 
molecular pathogenic mechanisms underlying the disease.  
The main aim of this research project was to identify novel genes 
associated to familial and sporadic forms of ALS by applying 
complementary approaches based on next-generation sequencing, thus 
overcoming the limitations of traditional genetic strategies.  
In particular we addressed two specific aims: 
 Identification of novel causative genes in familial ALS. 
Exome-sequencing was perfomed on familial cases, negative for mutations 
in known ALS-genes and collected through collaborations with other 
national and international ALS centers. The cohort included two ALS 
pedigrees displaying a dominant pattern of inheritance and 363 unrelated 
index FALS cases (one affected member for family), to reach an adequate 
number of affected individuals for a statistically powerful study. 
 
 Identification of potential DNMs in sporadic ALS 
A set of 32 ALS trios underwent exome-sequencing, according to the 
hypothesis that de novo mutations may contribute to the genetic basis of 
sporadic forms.  
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3.  MATERIALS AND METHODS 
3.1  Patients and controls   
The patient cohort consisted of patients with familial or sporadic ALS, 
collected from different centres in Italy, Europe e USA. All included patients 
fulfilled the El Escorial revised criteria [24] and were classified as having 
FALS according to the criteria of Byrne et al. [31]. Genomic DNA was 
extracted by peripheral blood after informed consent was obtained and all 
protocols were approved by the Institutional Review Boards at the 
institutions involved. FALS cases were prescreened for mutations in  the 
following ALS-causative genes, SOD1, FUS, TARDBP, C9ORF72, VCP 
and ANG genes, and individuals harbouring causative mutations were 
excluded from the study. SALS samples were analyzed for SOD1, FUS, 
TARDBP, C9ORF72.  
In particular, the cohort collected for exome-sequencing studies included: 
 Two large ALS families  of Caucasian (Family #1, Figure 5A) and 
Sephardic Jewish (Family #2, Figure 5B) origin,  displaying a dominant 
pattern of inheritance. DNA was available for 4 affected and 13 unaffected 
members of Family#1 and for 17 individuals (9 affected and 8 unaffected) 
of Family#2. In each family, the two affected members with maximum 
genetic distance were selected for exome-sequencing. 
 363 index unrelated FALS cases collected from several European 
countries and from USA (Table 2). 
 32 ALS trios, each constituted by the patient and both unaffected 
parents. The SALS group included 10 females and 22 males,  with an 
average age at onset of 41,0 ± 9,3 years (median 42,0 years), and a mean 
survival after the onset of first symptoms of  41,9 ± 21,7 months. None of 
the selected patients had cognitive impairment or dementia. Average age at 
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sampling for the unaffected parents was 74,8 years (72,0 for females and 
77,4 for males). The clinical characteristics of the enrolled patients are 
reported in Table 3. 
Moreover 31 controls samples (Table 2), ethnically-matched, and 9 FALS 
with known causative mutations (6 in SOD1 and 3 in VCP) were subject to 
WES. 
A second group of 272 FALS devoid of known mutations underwent to 
exome-sequencing and was used as replication panel.  Additional FALS,  
SALS samples and FTD patients (fulfilling the Neary criteria for FTD 
diagnosis) were included in the study for mutational screenings aimed to 
validate candidate ALS genes. 
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Figure 5.  Pedigrees of Family #1 and Family #2. Affected members are 
shown as black colored boxes, while the black dots indicate the family 
members whose DNA was available for the genetic study. Sex of pedigree 
members is obscured to protect privacy. Both ALS familial pedigrees show 
a dominant pattern of inheritance (A, B).  
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Table 2. Index FALS cases and controls collected for exome-
sequencing. All familial cases recruited resulted negative for mutations in 
known ALS-associated genes. 
 
 
Table 3. Demographic and clinical features of ALS trios.  
Patients  N° Age at onset         Site of onset  
   
 bulbar  spinal  
M 22       41.9      1    21 
F 10       42.6      3      7 
Total 32       41.8      4    28 
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3.2  Linkage analysis and exome-sequencing 
Linkage analysis 
Linkage analysis was perfomed on the available family pedigrees, Family#1 
and Family#2, by genotyping family members with Affymetrix 10K SNP 
arrays and analyzing data with the software application Allegro v.2.031 to 
generate multi-point LOD scores. Only affected members (and married-in 
samples) were used for the analysis. 
Exome-sequencing  
The targeted capture from genomic DNA was performed using the 
Nimblegen SeqCap EZ Exome Library, that containing 2.1 million long 
oligonucleotide probes provide the highest density coverage of RefSeq 
Coding Exons compared to other enrichment platforms (Illumina or Agilent). 
For FALS index cases and ALS trios samples, unique short sequences  
(barcodes) were attached to the adaptor region during the exome capture 
process to allow for multiplex sequencing. Short-read sequencing was 
performed on a HiSeq2000 instrument (Illumina) with an average coverage 
of 50X per exome. Exome sequencing reads were aligned to a human 
reference (hg19) using BWA (Burrows-Wheeler Aligner) and processed 
using the Genome Analysis ToolKit (GATK). After removal of duplicate 
reads, index realignment (GATK IndelRealigner), and base quality 
recalibration (GATK TableRecalibration) was performed. Variant detection 
and genotyping were performed using the UnifiedGenotyper (UG) tool from 
GATK. Variants not passing quality control criteria were eliminated 
(QD<5.0, HRun>3, MQ<40.0, FS>60.0, HaplotypeScore>13.0, 
MQRankSum< -12.5, ReadPosRankSum< -8.0) and genotypes with low 
quality (GQ<50) were set to missing. 
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3.3 Data analysis strategies  
Data analysis and variant filtering pipelines were handled differently for the 
three subsets (FALS pedigrees, index FALS and ALS trios).  
FALS pedigrees 
To reduce the number of candidate variants from the initial set identified in 
every individual by WES, different filtering steps were applied,  as reported 
in previous exome sequencing studies [76,77]. Based on the main 
assumptions that the causal variant alters the protein-coding sequence and 
is not present in the general control population, the non-coding variants or 
SNPs identified in dbSNP132, the 1000 Genomes Project (May 2011 
release), or the NHLBI ESP Exome Variant Server (5,379 sequenced 
exomes) were excluded. We then filtered out variants that were not shared 
by both affected members of each family or variants not in according to the 
dominant inheritance pattern or excluded by linkage analysis. The steps are 
shown in Table 5. Candidate variants identified by filtering were validated 
using bidirectional Sanger sequencing with customized primers in the  
patients with exome sequence data and tested for segregation in the 
additional affected members of the Family#1 and Family#2.   
FALS unrelated 
Samples with low call rate(<0.75), showing relatedness to another sample 
(IBD>0.2), with discordant phenotype-genotype gender, with excess 
homozygosity/heterozygosity or outliers from stratification analysis were 
eliminated resulting in the final set of FALS samples used for the next 
analysis. 
A rare variant analysis was performed by logistic regression of case-control 
status with respect to the aggregated count of minor alleles in a given gene 
window. Regression was performed using Firth's penalized likelihood 
method to avoid errors of model fitting in the event of data separation 
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(where gene variants occur exclusively in the case or control cohort). For 
controls, genotype data from 4300 European Americans were obtained 
from the NHLBI’s Exome Variant Server. These genotypes were randomly 
assigned to 4300 simulated individuals. Variants were filtered to those 
showing 90% call rate in either ESP data set or FALS. Gene selection was 
based on the initial set that passed quality control standards of the ESP 
study (14,931 autosomal genes). These genes were further restricted to 
those which displayed an 85% call rate over 85% of the coding region in 
the EVS resulting in the final set of 12,224 genes subject to rare variant 
analysis.  
Variants were annotated as damaging by PolyPhen2 (score> 0.446) or 
representing stop gain/loss variants. Additional filtering procedures included 
SIFT (“damaging”), Mutation Taster ("disease causing automatic" or 
“disease causing”), GERP (GERP++ score>0), and phyloP (score>0). 
Variants that did not display a 90% call rate in either cases or controls were 
eliminated from the analysis. Gene windows and predicted variant effects 
were defined based on protein coding RefSeq transcripts only. Variants 
were only included for analysis if the associated minor allele frequency did 
not exceed what would be expected of a typical ALS mutation on the basis 
of prior publications. Specifically, Mendelian ALS variants identified to date 
have generally been reported to account for <1% of population based 
patient cohorts8,9. The lifetime risk of ALS is ~1/40039, meaning that even 
in the event of penetrance as low as 50%, it would not be expected to 
observe a given ALS mutation in more than a single control (p<0.05). To 
allow for the potential of a single control occurrence and up to 3 case 
occurrences (~1% of patients), a maximum minor allele frequency of 
0.0004 (4 occurrences) was imposed. Multiple testing correction was 
performed through repetition of regression analyses with prior permutation 
of case-control status. Reported family-wise error rates represent the 
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proportions of permuted datasets wherein any gene exhibited an 
association of equal or greater significance. The genomic inflation factor 
was calculated as previously described. All data processing and rare 
variant analyses were performed using scripts prepared for bash version 
4.2.24, python version 2.6.5 and R version 3.0.1. 
Trios samples 
On  each trios sample, paternity and maternity was verified by checking the 
percentage of shared heterozygous mutations between child and 
mother/father. Predicted de novo events were identified as sites where both 
parents were homozygous for the reference sequence and the offspring 
was heterozygous.  To identify rare private variants, the full variant list was 
compared against dbSNPv135, the NHLBI Exome Sequencing Project and 
the 1000 Genomes Project. 
3.4 Bioinformatic analysis 
The effect of missense variants on protein structure and function was 
predicted by using different bioinformatic tools: SIFT (Sorting Intolerant 
from Intolerant), an evolutionary conserved based method, and PolyPhen-
2, a prediction tool which evaluate also the physic-chemical characteristics 
of the amino-acid involved in the substitution and other structural 
parameters. The gene function analysis and the functional classification 
according to the molecular function was performed by using Panther 
(Protein ANalysis THrough Evolutionary Relationships). Two different  gene 
network tools, DAPPLE (Disease Association Protein-Protein Link 
Evaluator) and GeneMania, were used to construct networks using the list 
of genes of interest and the subset of known ALS-causative genes. 
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3.5 Sanger sequencing and genotyping 
Sanger sequencing was applied to samples to validate the candidate 
variants indentified by WES and to exclude possible false positive. Further,  
the mutational screening of candidate genes (PFN1, TUBA4A) was 
performed by direct sequencing on additional ALS cases, FTD patients and 
controls.                        
The entire coding regions of  PFN1 and TUBA4A and at least 30 bp of the 
flanking intronic sequences were amplified by polymerase chain reaction 
(PCR) using AmpliTaq Gold (Applied Biosystems) or AccuPrime GC-rich 
Polymerase (Invitrogen). Amplification primers are shown  in Table 4.   
The PCR products were subsequently purified by incubation with Illustra 
Exonuclease I and Alkaline Phosphatase (GE Healthcare) to remove 
unincorporated primers and dNTPs, and then sequenced using the BigDye 
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and  run on a 
capillary sequencer (Applied Biosystems). All identified sequence variations 
were confirmed by sequencing an independent PCR product.  
Control DNA samples were tested by direct sequencing  or by SNP 
genotyping using TaqMan Assay.  
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Table 4. Primer sequences and PCR conditions for amplification of 
PFN1 and TUBA4A coding regions.  
Gene Exon Primer sequence 
(5’  3’) 
Amplicon 
length (bp) 
Annealing 
temperature
(C) 
  
 
1 
 
Fwd:  CAGCTCGAGCCCAGTCC 
 
 
 
254 
 
 
60 
  Rev: AAGTCCCTCCCTCAGGGTC 
     
PFN1  
 
2  
 
Fwd: GGAGAACACGGTGGGAATC 
 
 
330 
 
 
58 
  Rev:CACCCTCAAGATTACCAGAAGG 
     
  
 
3  
 
Fwd: GGGTGGAATTGTGACACCTG 
 
 
223 
 
 
 
58 
  Rev: TTTGTGTGTGTATGGGGAGG 
     
      
  Fwd:  CAGCCTCTAGTGGGCGAGC  
262 
 
60  1  
Rev:  CTCGCACCTCCTGGAGAC 
     
TUBA4A   
Fwd: AGCTGGTAGATGATAGGGTGG 
 
 
845 
 
 
60  2/3  
Rev: GATGACCTCCTGAAAGGATCTG 
     
  
 
4 
 
Fwd:CTGACTGCTGATGTATCTTACGC  
 
Rev:AGCAGAAGCTCAAGCACTCAGAGG 
 
 
1175 
 
 
61 
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3.6 Cell cultures and transfections 
The mouse neuroblastoma cell line N2A was grown  in MEM supplemented 
with 10% fetal bovine serum, 2mM L-glutamine, 100 units/ml penicillin and 
100 μg/ml streptomycin at 5% CO2. HEK293 cells were maintained in 
DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin 
and 100 µg/ml streptomycin at 5% CO2.  
Primary motor neurons (PMNs) were isolated from E12.5 mouse embryos: 
spinal cords were dissociated in 0.1% trypsin for 12 minutes at 37ºC, and 
motor neurons were isolated by density centrifugation on a 6% Optiprep 
(Sigma-Aldrich) cushion. Primary motor neurons were maintened in 
Neurobasal medium supplemented with 2% horse serum, 2% B27, 10nM 
BDNF, CNTF, GDNF).  
PFN1 expression vectors with V5 epitope tags were constructed using the 
backbone pcDNA3.1/nV5-DEST (Invitrogen) by way of Gateway 
Technology according to manufacturer’s protocol. For establishment of 
mutant Profilin1 plasmids, site-directed mutagenesis was performed on 
wild-type vector using Quickchange Multi Site-Directed Mutagenesis Kit 
(Agilent) according to manufacturer’s protocol. TUBA4A expression 
constructs  were created by synthesizing the wild-type and mutant coding 
region with an HA epitope tag at the N-terminus (DNA2.0) and subcloning 
into the vector pJ603. 
For Western Blotting experiments, transfections of N2A and HEK293 cells 
were performed in 6-well plates with 3 μg of plasmid DNA using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. 
For immunofluorescence, cells were plated in 12mm round coverslips in 24-
well plates and transiently transfected with 0.8 μg of plasmid DNA plasmids 
using Lipofectamine 2000 (Invitrogen).  
PMNs were transfected using paramagnetic nanobeads (NeuroMag, Oz 
Biosciences) as previously described  [86]. 
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3.7  Immunofluorescence 
At 48h after transfection, N2A cells were fixed with 4% paraformaldehyde 
for 15 minutes, permeabilzed  with 1% Triton X-100 at room temperature 
for 10 minutes, and then blocked with blocking buffer (50 mM NH4Cl, 10 
mg/ml BSA, 2% natural goat serum, 0.1% Triton X-100 in DPBS) at 37°C 
for one hour. Cells were then incubated with a fluorescent-conjugated 
primary antibody (mouse Dylight 549-V5 antibody, rabbit Dylight 488-
ubiquitin antibody) at 4°C overnight. After the incubation, cells were washed 
three times with PBST (0.1% Tween-20), and the coverslips mounted with 
Vectashield Hard Set Mounting Medium containing DAPI (Vector 
Laboratories).  Similarly,  immunofluorescence experiments were also 
conducted on primary motor neurons transfected by magnofectin.  
HEK293 cells were fixed 48-hour after transfection with 4% 
paraformaldehyde at room temperature for 15 minutes, permeabilized with 
cold methanol for 10 minutes and 0.3% Triton X-100 at room temperature 
for 5 minutes followed by blocking with 10% normal goat serum solution in 
PBS at room temperature for 20 minutes. Incubation with primary antibody 
(anti-HA, 1:100, Sigma) was performed in blocking solution for 1.5 hour at 
37°C and the fluorescent secondary antibody AlexaFluor 488 (1:500, 
Invitrogen) was used for detection. Slides were mounted with ProLong Gold 
antifade reagent containing DAPI to visualize the nuclei.   
Confocal images were obtained by Leica  or Nikon TE-2000E2 microscope.   
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3.7 Soluble/ insoluble fractionation  
NP40 soluble/insoluble fraction 
After transfection, N2A cells were directly collected in NP-40 lysis buffer 
(1% NP-40, 20 mM TrisHCl pH. 7.4, 150 mM NaCl, 5 mM EDTA, 10% 
glycerol, 1mM DTT, 10 mM sodium fluoride, 1 mM sodium orthovanadate, 5 
mM sodium pyrophosphate) additioned with EDTA free protease inhibitors 
(Roche).  After sonication, the lysate was rotated for 30 minutes at 4°C 
followed by centrifugation at 13,500 rpm for 20 minutes. The supernatant 
(‘soluble fraction’) was collected into a new tube, while the remaining pellet 
was washed once with 1 ml of lysis buffer and then resuspended in 8M 
urea/3% SDS buffer followed by sonication (‘insoluble fraction’). The 
soluble/insoluble fractions were analzyed by Western Blotting using the 
mouse monoclonal anti-V5 (1:2000, Invitrogen) antibody to detect PFN1. 
GAPDH  was used for normalization.  
 
Differential solubilization  
TUBA4A transfected HEK293 cells were collected  at 48h in 300μl PBS 
buffer with protease inhibitors (Sigma), sonicated and centrifuged at 
13,500xg for 10 minutes at 4°C. The supernatant was collected as the 
PBS-soluble fraction. The remaining pellet was sequentially resuspended in 
100μl 1% Triton X-100, 5% SDS, and 8M urea, sonicated and centrifuged 
at 13,500xg for 10 minutes at 4°C. Lysate were run on a 10% 
polyacrylamide gel with equivalent volumes loaded of the soluble and 
insoluble fractions per each sample. For Western Blotting analysis the 
following antibodies were used: mouse anti-HA (Cell Signaling Cat. No 
2367) and IRDye 680 anti-mouse secondary antibody for detection (Licor); 
rabbit GAPDH and rabbit Lamin (used as controls) and 800 anti-rabbit 
secondary antibody (Licor). 
 
48 
 
3.8  Immunoprecipitations 
 
V5-PFN1 transfected HEK293 cells were lysed at 24 hours with RIPA buffer 
and immunoprecitated with 1μg of anti-V5 antibody overnight at 4°C 
followed by incubation with Dynabeads Protein G for 1 hour. The protein-
bead complexes were washed four times with RIPA buffer, eluted by boiling 
at 95°C for 5 minutes and then subject to western blot analysis to detect 
V5-PFN1 and actin. The following antibodies were used: mouse anti-V5 
(1:5000, Invitrogen), mouse anti-beta actin (1:1000, Sigma), goat anti-
mouse 800CW (1:10000, LICOR). 
 
3.9  Tubulin Dimerization Assay  
In vitro translation of HA-TUBA4A constructs was performed using the TNT 
T7 Coupled Reticulocyte Lysate system (Promega). For non-denaturing gel 
electrophoresis, the products were diluted 1:1 in sample buffer (160 mM 
MES pH 6.86, 2mM MgCl2, 2 mM EGTA, 1 mM GTP, 20% Glycerol), 
immediately loaded onto a non denaturing gel (4.5% polyacrylamide in 
80mM MES pH 6.86, 1mM MgCl2, 1mM EGTA, 1mM GTP) and run at 95 
volts for 1.5 hours. For SDS-gel electrophoresis, the reaction products were 
diluted in 2X  Laemmli buffer, boiled for 5 minutes and loaded onto a 4-
20% Mini-PROTEAN TGX gel (Bio-Rad). Proteins were transferred to a 
0.45 μm nitrocellulose membrane for 10 minutes at 1.2 amp/25 volts on the 
Trans-Blot Turbo Transfer System (Bio-Rad). HA-TUBA4A was detected 
via chemiluminescence using mouse HA antibodies (MMS-101R-200, 
Covance), goat anti-mouse HRP conjugate (sc-2005, Santa Cruz) and 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 
Scientific). 
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4. RESULTS 
We performed an exome-sequencing study to identify novel causative 
genes in familial and sporadic ALS and applied specific analysis strategies 
modeled on different study designs. 
4.1 Exome sequencing of ALS families identifies mutations in 
PFN1 gene 
In the first phase of our study, we investigated 2 large dominant  ALS 
families of Caucasian (Family #1, Figure 5A) and Sephardic Jewish (Family 
#2, Figure 5B) origin, negative for mutations in known ALS-associated 
genes (SOD1, C9orf72, TARDBP, FUS, ANG). A combined strategy of 
whole-exome sequencing and linkage analysis was employed to identify 
the underlying mutations. Exome-sequencing was performed on the two 
affected members from each family with maximum genetic distance (III:8 
and III:12 in Family#1, II:4 and II:11 in Family#2). A high level of coverage 
(>150X) was achieved with an average of 1.1 × 1010 and 2.3 × 1010 base 
pairs sequenced for Families #1 and #2, respectively. After filtering to 
exclude variants reported in public databases (dbSNP132, 1000 Genomes 
Project, NHLBI ESP Exome Variant Server) and combining data with 
linkage analysis,  we observed 2 and 7 heterozygous coding variants in 
Family#1 and Family#2 respectively, shared by both affected members in 
each family (Table 5). Validation by Sanger sequencing in the probands 
and proof of segregation of the variants in additional affected members 
reduced the list of candidates to two variants in Family #1 and three 
variants in Family #2 (Table 5). Interestingly, both families harbored 
different mutations (C71G and M114T) within the same gene PFN1, 
profilin-1 (Table 6).  
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Table 5. Filtering steps applied to variant detected by WES in FALS 
pedigree. The table reports the number of variants left after each filtering 
steps. The regions with LOD score>zero were calculated on linkage 
analysis of FALS pedigrees. 
 
FILTER Family #1 Family #2 
Total variants 282.782 382.751 
Coding variants   29.777    42.661 
Overlapping variants       9.045    10.669 
Novel variants           18         178 
Heterozygous/Non-synonymous variants           10         135 
Lod score>0              2             7 
Confirmed by Sanger sequencing             2             6 
Mendelian segregation              2             3 
Totale            2            3 
 
Table 6. Candidate causal genes for familial ALS after filtering steps.   
 Gene  Description Mutation SIFT 
 PFN1 Profilin-1 C71G damaging 
Family #1 XPOT tRNA exportin V139A tolerated 
 
FMO2 
Dimethylaniline  
mono-oxygenase 2 T390I tolerated 
Family #2 KIF1C Kinsesin-like protein 
KIF1C 
I118L tolerated 
 PFN1 Profilin-1 M114T damaging 
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PFN1, located on chromosome 17p13.2, encodes for a 140 amino acid 
protein regulating monomeric (G)-actin conversion to filamentous (F)-actin 
filamentous [87]. Based on these data, we postulated that mutations in the 
PFN1 gene can cause familial ALS. 
To further investigate the causative role of PFN1 gene in ALS, we 
sequenced  the entire coding region in a large cohort of 272 index FALS 
cases and identified five additional cases harboring alterations in PFN1. 
The C71G missense mutation, originally identified in Family #1,  was 
detected  in two additional families (Family #3 and Family #5, Figure 6) and 
segregated with the disease in Family #3, in which three other affected 
family members were available for testing. The other mutations included: a 
M114T variant, identified in two affected siblings of an ALS family of Italian 
origin (Family #4, Figure 6); a consecutive base pair change (AA to GT) 
resulting in a E117G mutation and a G118V mutation.   
 
Given that many familial ALS-associated genes account also for a small 
percentage of sporadic cases, we investigated the genetic contribution of 
PFN1 also in sporadic ALS. Sequencing of the entire coding region in a 
large cohort of 1984 SALS resulted in the identification of the variant 
p.E117G in three additional cases. 
 
In total, we identified 4 different PFN1 mutations in 7/274 FALS cases 
(2.6%) and the E117G variant in 3/1984 SALS (Table 7): all mutated cases 
but one had spinal onset ALS and none manifested signs of dementia. The 
clinical phenotype of the patients carrying PFN1 mutations is reported in 
Table 8. Considering the great pathological and genetic overlap between 
ALS and FTD, we extended the analysis of PFN1 gene to 203 FTD patients 
(of whom 30 represented familial cases) but we failed to identify any 
mutation (Table 7). 
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Three of the ALS-related mutations (C71G, M114T, G118V) were not found 
in a total of 9072 controls, including 2601 individuals analyzed in-house by 
genotyping or Sanger sequencing and 6471 controls available through 
1000 Genomes Project database and NHLBI ESP Exome Variant Server 
(Table 7). Conversely, the E117G variant was observed in 3/9072 control 
subjects, with an allele frequency of 1.77 × 10−3 in ALS vs 3.03 × 10−4 in 
controls. 
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Figure 6. Pedigrees of families with additional PFN1 mutations. 
Pedigrees of Families #3-7, harbouring PFN1 mutations, are shown. The 
gender of the pedigree members is obscured to protect privacy. Mutant 
alleles are indicated by mut, whereas wild-type alleles are indicated by wt. 
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Table 7. Results of PFN1 mutational screening in FALS, SALS, FTD 
patients and controls.  
Mutation                Patients                            Controls  
 FALS  SALS   FTD  1000 
Genome 
ESP  Genotyping/   
Sequencing  
Total  
C71G  2/274  0/1984   0/203  0/1092  0/5379  0/2601  0/9072  
M114T 1/274  0/1984  0/203 0/1092 0/5379 0/2601  0/9072 
E117G  1/274  3/1984   0/203 0/1092 2/5379 1/2601  3/9072  
G118V  1/274  0/1984   0/203 0/1092 0/5379 0/2601  0/9072 
 
Table 8. Clinical phenotype of ALS patients harbouring PFN1 
mutations 
Patients  Mutation  
Age of Onset 
(yrs) Site of Onset Dementia No. Pts  
Family # 3  C71G  41.1 +/- 4.3  spinal  no  4  
Family # 1 C71G  50.0 +/- 6.6  spinal no  4  
Family # 5 C71G  44.0  spinal no  1  
Family # 2 M114T  41.9 +/- 5.3  spinal no  7  
Family # 4 M114T  52.0 +/- 13.1  spinal no  3  
Family # 7 E117G  40.3  spinal no  1  
Family # 6  G118V  43.0  spinal no  1  
      SALS# 1  E117G  63.0  spinal no  1  
SALS# 2 E117G  33.9  spinal no  1  
SALS# 3 E117G  72.0  bulbar  no  1  
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4.2 PFN1 mutants are aggregation prone and show alterations in 
actin binding. 
In light of these genetic findings, a functional characterization of the 
identified ALS-associated variants was conducted to investigate their 
potential pathogenicity in ALS.                                                            
Since misfolding and aggregation are key features demonstrated for many 
ALS-linked proteins (including FUS, SOD1, OPTN, UBQLN2,  
HNRNPA2/B1, VCP),  we started to investigate whether mutations reduce 
profilin-1 solubility, inducing the formation of insoluble aggregates.   
To test this hypothesis we performed a Western-blot analysis of NP-40-
soluble and insoluble fractions of N2A cells transfected with wild-type (WT) 
or mutant PFN1. Compared to WT PFN1, which was present predominantly 
in the soluble fraction (Figure 7a), PFN1 mutants were considerably 
detected in the insoluble fractions, where several higher molecular weight 
species (indicative of SDS-resistant oligomers) were also observed. Only 
the E117G mutant displayed a pattern more similar to wild-type PFN1 with 
most of the expressed protein in the soluble fraction. Impairment of 
ubiquitin-proteosome system induced by treatment with MG132 resulted in 
increased levels of PFN1 mutants in insoluble fraction (Figure 7b). 
The propensity of PFN1 mutant to form insoluble ubiquitinated aggregates 
was further investigated by immunostaing profilin-1 in transfected NA2 cells 
and primary motor neurons. In N2A cells wild-type PFN1 exhibited a diffuse 
cytoplasmic localization but, in contrast, 15-61% of mutant expressing cells 
displayed ubiquitinated cytoplasmic aggregates containing profilin-1 (Figure 
8a-b). Similar ubiquitinated aggregates  were observed in primary motor 
neurons (PMNs) expressing the C71G, M114T, and G118V PFN1 mutants, 
while aggregates were not observed in cells expressing WT and E117G 
construct (Figure 8c). Co-aggregation of TDP-43 with mutant PFN1 was 
observed (Figure 8d).  
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Figure 7. Different solubility of PFN1 mutants. Western blot analysis of 
NP-40 soluble and insoluble fractions  in transfected N2A cells not  (a) or 
treated with MG132 (b). 
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Figure 8. Mutant PFN1 produces ubiquitinated insoluble aggregates. 
(a-b) Transfected N2A cells were stained with V5 and ubiquitin antibodies 
and cell displaying insoluble aggregates were counted and analyzed using 
one-way ANOVA testing with Dunnett’s multiple test comparison (n=127-
135 transfected cells from 3 independent experiments). *P<0.05, 
***P<0.001, n.s. P>0.05. Error bars indicate SEM. (c,d) Transfected PMNs 
stained with V5 and TDP-43 antibodies. Scale bars: 5 µm (a), 10 µm (c, d) 
 
58 
 
PFN1 plays an important role in actin polymerization by catalyzing ADP-to-
ATP exchange on G-actin and adding ATP-G-actin to the barbed ends of 
actin filaments. Therefore, we evaluated the possible pathological effects of 
mutated PFN1 on actin polymerization. Since structural analysis of the 
profilin1-actin complex showed that all ALS-linked mutations lie in close 
proximity to the actin binding domain of profilin-1 (Figure 9a), we conducted 
a co-immunoprecipitation assay to test the actin binding ability of each 
mutant. The synthetic H120E PFN1 mutant, known to abolish the binding to 
actin, was used in experiments as positive control [88]. After performing co-
immunoprecipitation experiments using lysates of transfected HEK293 cells 
and Western Blot analysis, we observed that the C71G, M114T, G118V 
and H120E mutants displayed reduced levels of bound actin compared to 
WT profilin-1(Figure 9b). The E117G mutant did not display a reduction in 
actin binding compared to the wild-type counterpart. 
Since previous reports revealed that expression of profilin-1 mutants 
defective in actin binding decreases neurite length and strongly inhibits 
filopodia formation [78], the effect of ALS-linked PFN1 mutants on neurite 
outgrowth was evaluated by measuring axonal length in transfected PMNs. 
Three mutants (C71G, M114T, and G118V) induced a significant decrease 
in axon outgrowth, similar to the reduction observed for the H120E 
construct (Figure 10). Axon outgrowth inhibition was observed also with the 
E117G mutant, although not reaching statistical significance.   
Together, these results suggest that ALS-associated PFN1 mutations 
display several functional defects linked to ALS pathogenesis: an increased 
aggregation propensity in cell cultures and an altered actin-binding ability 
with inhibitory effect on axon outgrowth. According to experimental 
observations, p.E117G is likely variant with reduced pathogenic potential, 
since it exhibits only moderate aggregation propensity and does not affect 
actin binding and polymerization.  
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Figure 9. PFN1 mutations display reduced acting-binding ability. (a) 
PFN1-actin interaction region using the PyMOL Molecular Graphics System 
(v. 1.4). Magenta:actin; Yellow:PFN1; Green:actin-binding PFN1 residues; 
Red: ALS-linked mutated PFN1 residues; (b) Cell lysates of transfected 
HEK293 cells were immunoprecipitated with anti-V5 antibody and then 
analyzed by immunoblotting with antibodies as indicated. 
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Figure 10. Mutant PFN1 inhibits axon outgrowth. PMNs transfected with 
wild-type or mutant V5-PFN1 and a GFP expressing construct were stained 
to detect V5-PFN1. The axon tip, indicated by arrows, is enlarged in the 
inset in right panel. Cumulative distribution of axon lengths relative to the 
mean of wild-type PFN1 transfected cells was plotted.P values are given in 
the legend (n=104-161 cells from 4 independent experiments). Scale bar: 
100 μm. 
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4.3 Exome sequencing of unrelated FALS indentifies TUBA4A as 
candidate gene  
Because of the difficulty in collecting an adequate number of multi-
generational FALS informative pedigrees, we also sequenced the exomes 
of 363 index familial cases (one affected sample per family) with unknown 
genetic cause and included  9 FALS with known causative mutations (6 
mutated for SOD1 and 3 for VCP) as positive controls. An average of       
3.2 x 109 target bases were sequenced per sample to an average depth of 
90.4X. Filtering steps led to the elimination of variants not passing quality 
control criteria (QD<5.0, HRun>3, MQ<40.0, HaplotypeScore>13.0, 
FS>60.0, , MQRankSum< -12.5, ReadPosRankSum< -8.0) and to the 
exclusion of samples with low call rate. An exome-wide rare variant 
analysis, comparing the total number of gene variants seen among 
unrelated cases and controls, was performed to identify potential candidate 
genes. The controls were represented by 31 healthy samples sequenced in 
house and by 4300 European Americans individuals from the NHLBI’s 
Exome Variant Server (EVS). The analysis was performed for 12,495 
genes fulfilling all quality control filters and restricted only to variants with a 
MAF <0.0004 in EVS and predicted to be damaging using PolyPhen-2 or 
resulting in a stop gain/loss.  
As shown in Figure 11, SOD1 gene (6 cases [1.6%] vs 0 controls, P=5.5 x 
10-8, Pcorrected=6.2 x 10
-4) ranked  first and VCP (3 cases [0.8%] vs 0 
controls, P=1.1 x 10-4, Pcorrected=0.73) ranked tenth among all genes 
confirming the validity of our approach. After SOD1, the top hit was 
TUBA4A, encoding for Tubulin, Alpha 4A (4 cases [1.1%] vs 0 controls, 
P=9.1 x 10-6, Pcorrected=0.09). The gene was well covered by EVS confirming 
that the P-value was not inflated due to poor control sequencing. Although 
TUBA4A was the most consistent hit, the analysis identified other possible 
candidate genes for FALS, including MATR3 which was recently 
recognized as FALS-causative gene by exome-sequencing [89].  
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Five different TUBA4A variants were identified by exome-sequencing in 
363 FALS: all mutations were confirmed by Sanger sequencing in relevant 
cases and were located in the last exon of the gene, affecting evolutionary 
highly conserved residues (Figure 12). Then nonsynonymous substitutions 
included 4 missense mutations (R215C, R320C, R320H, A383T) and 1 
nonsense mutation (W407X) removing the last 41 aminoacids of the C-
terminal region. Unfortunately, no DNA was available from additional 
affected relatives to test segregation. None of these mutations were 
observed in the 4300 European American EVS controls, in which only  
three non-synonymous changes (not predicted to be damaging)  were 
observed.  
To further investigate the role of TUBA4A as an ALS causative gene, we 
sequenced an independent replication panel of 272 index FALS cases and 
identified two additional variants (T145P, K430N) in two FALS: the mutation 
T145P was predicted to be probably damaging by PolyPhen-2 
(score=0.998) and segregated in the affected parent of the proband; the 
other variant K430N was not observed in the affected first cousin of the 
proband, representing probably a neutral rare polymorphism. By extending 
our mutational analysis to 1355 SALS, we identified another mutation 
(G43V) in one sample: this variant was predicted to be benign according to 
PolyPhen-2. 
Five FALS-related TUBA4A mutations (T145P, R215C, R320C/H, W407X) 
were not found in a total of 13,063 control samples, including 4500 
European Americans and 2200 African Americans individuals available 
from EVS, 1053 individuals from 1000 Genome Project and 5510 European 
Americans subjects sequenced in house (Table 9). However, the G43V and 
A383T substitutions were observed in a single Italian and an African 
American control, respectively.  
 
63 
 
Figure 11. Rare variant analysis identifies TUBA4A mutations in FALS. 
Manhattan plot displaying permutation-based corrected P values generated 
by a rare variant analysis of FALS. The dotted line represents a 
Pcorrected=0.05.                        
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Figure 12. Evolutionary conservation of  TUBA4A residues affected by 
mutation. Aminoacid alignment of TUBA4A protein showing conservation 
of mutates residues in different phyla. The mutated residue is in red. 
 
 
Table 9. Analysis of TUBA4A mutations in controls. To confirm that the 
newly identified TUBA4A variants represent causal mutations, 5510 
Caucasian controls were directly sequenced and each variant was  
interrogated in the 1000 Genomes Project database and the NHLBI ESP 
Exome Variant Server. 
Mutation EVS-EA EVS-AA 1000 Genome 
Project 
Internal 
controls 
Total 
G43V 0/4300 0/2200         0/1053 1/5510 1/13063 
T145P 0/4300 0/2200 0/1053 0/5510 0/13063 
R215C 0/4300 0/2200 0/1053 0/5510 0/13063 
R320C 0/4300 0/2200 0/1053 0/5510 0/13063 
R320H 0/4300 0/2200 0/1053 0/5510 0/13063 
A383T 0/4300 1/2200 0/1053 0/5510 1/13063 
W407X 0/4300 0/2200 0/1053 0/5510 0/13063 
K430N 0/4300 0/2200 0/1053 0/5510 0/13063 
 
EVS (Exome Variant Server, NHLBI GO Exome Sequencing Project) 
EA (European-Americans), AA (African-Americans) 
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The clinical features of ALS patients carrying TUBA4A mutations are shown 
in Table 10. All the patients had spinal onset ALS with upper and lower 
motor neuron signs. Two cases developed a cognitive decline of frontal 
type, consistent with a diagnosis of frontotemporal dementia (FTD) and 
another reported a first-degree relative with FTD, suggesting that TUBA4A 
mutations may also contribute to FTD pathogenesis  
 
 
Table 10. Clinical characteristics of ALS patients with TUBA4A 
mutations. Disease duration is calculated in months to the last follow-up.  
 
Mutation 
Family 
history 
Other ND 
family history 
Age of 
onset 
Site of 
onset 
Disease 
durarion 
(months) 
Dementia 
G43V SALS dementia 52 spinal 45 FTD 
T145P FALS dementia 48 spinal 69       no 
R215C FALS dementia 78 spinal n/a FTD 
R320C FALS no 64 spinal 12       no 
R320H FALS no 41 spinal 33 no 
A383T FALS    no    71 spinal    18 no 
W407X FALS no 66 spinal 36 no 
K430N FALS no 64 spinal 42 no 
 
ND (neurodegenerative disorders)  
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4.4 TUBA4A mutants affect microtubule polymerization 
Based on these genetic finding, we explored the functional consequences 
of mutations in TUBA4A. Since several causative ALS proteins, including 
profilin-1, have been shown to form insoluble inclusions in cell culture, we 
assessed the tendency of the TUBA4A mutants to aggregate.    
After transfecting HEK293 cells with WT and mutant HA-tagged TUBA4A 
constructs, we performed a Western Blot analysis of fractions obtained by 
differential solubilization in four different buffers (PBS, Triton X-100, SDS, 
urea). We observed that the majority of W407X mutant protein was 
insoluble in Triton X-100 being detected prevalently in the SDS and urea 
fractions. The other mutants (G43V,R215C, R320C/H, A383T) displayed no 
significant differences in solubility compared to WT (Figure 13). 
Additionally, the formation of insoluble aggregates was further investigated 
by immunostaining HEK293 cells and primary motor neurons (PMNs) 
transfected with TUBA4A constructs. Consistent with the results obtained in 
soluble/insoluble fractionation experiments, we observed that the W407X 
mutant did not incorporate into the microtubule network and formed small 
ubiquitinated cytoplasmic inclusions in ~85% of transfected HEK293 cells 
and in ~40% of transfected PMNs (Figure 14). The other TUBA4A mutants 
formed cytoplasmic inclusions in only 10-30% of transfected HEK293 cells 
(Figure 14) while no aggregation was observed in PMNs. However, subtle 
alterations in TUBA4A cytoplasmic distribution were observed, such as a 
more diffuse cytoplasmic staining compared to the wild-type protein, which 
was mainly distributed within the microtubule network. 
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Figure 13. Protein fractionation of TUBA4A mutations.  (A) HEK cells 
were transfected with constructs expressing wild-type or mutant TUBA4A. 
Cellular lysates were subject to sequential precipitations and resuspensions 
using the buffers indicated and immunoblotted with anti-HA anitibody. (B) 
Expression levels were quantified and the percent of the total HA-TUBA4A 
protein was calculated. Bars represent mean and SEM (one-way ANOVA 
and Dunnett’s post hoc test, n=3, ** P<0.01). 
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Figure 14. Mutant TUBA4A W407X  forms ubiquitinated agreggates. (a) 
HEK293 cells transfected with wild-type or mutant HA-TUBA4A constructs 
were immunostained for HA. TUBA4A-positive aggregates were particularly 
abudant in the cells trasnfected with W407X mutant. (b) PMNs transfected 
with HA-tagged TUBA4A constructs. The presence of TUBA4A and 
ubiquitin postive aggregates was oberved only for the mutant W407X. 
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The protein encoded by TUBA4A belongs to the tubulin superfamily and is 
a major constituent of microtubules, which are involved in many cellular 
processes (including mitosis, cell motility, intracellular transport, secretion, 
maintenance of cell shape and cell polarization). In particular microtubules 
are composed by alpha- and beta-tubulin heterodimer subunits assembled 
into linear protofilaments.  Therefore, we started to investigate the ability of 
TUBA4A mutants to be efficiently incorporated in alpha/beta tubulin dimers 
by performing an in vitro translation in rabbit reticulocyte lysate, which 
contains all the components needed to form tubulin dimers. The analysis of 
the reaction products in denaturating conditions (SDS-PAGE) showed that 
the translation efficiency of all the mutants was similar to the wild-type 
(Figure 15). The same reaction products were then analyzed by non-
denaturing gel electrophoresis to measure incorporation of the translated 
recombinant protein into tubulin heterodimers. The mutant protein W407X, 
which deletes the C-terminal region interacting with β-tubulin, did not form 
heterodimers at all, while two other mutants, A383T and R320, displayed 
an impaired dimer formation compared to the WT protein (Figure 15). The 
other mutants did not differ significantly from the control. 
The functional characterization of TUBA4A mutants was extended to test 
their capacity in vivo to incorporate into the microtubules of transfected 
primary glial cells, which have a large cytoplasm and a relatively long cell 
cycle that result in a extensive and stable microtubule network. According 
to the distribution and microtubule incorporation of HA-tagged TUBA4A, the 
cells were classified into four categories (normal, mild, moderate, severe). 
Contrary to the wild-type protein, the R320C/H, A383T and R215C mutants 
all displayed a significantly different distribution and a defective 
incorporation into microtubules (Figure 16). In particular, we found that the 
W407X mutant failed to be incorporated in microtubules, showing a diffuse 
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distribution throughout the cytoplasm and the presence of small aggregate-
like inclusions. No difference was detected for the G43V mutant.  
Together, these results suggest that ALS-associated TUBA4A mutations 
exhibit several defects, from the aggregation propensity of the truncated 
protein W407X to the mild or more severe deficiencies showed also by the 
other mutants in heterodimerization and microtubules formation. 
 
Figure 15. Effects of TUBA4A mutations on tubulin  
heterodimerization. Non-denaturing (top) and SDS-gel electrophoresis 
(bottom) of HA-TUBA4A constructs after in vitro translation. The intensity of 
the bands representing the α/β tubulin dimers was quantified from 6 
independent experiments. Bars represent mean and SEM (one-way 
ANOVA and Dunnett’s post hoc test, * p<0.05, *** p<0.001). 
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Figure 16. Mutant TUBA4A alters microtubule polymerization Primary 
glial cells were transfected with the HA-TUBA4A constructs and fixed 4 
days after transfection. The distribution of the HA-TUBA4A protein was 
classified as normal, mild (subtle diffuse staining), moderate (significant 
diffuse staining), or severe (no visible HA-positive microtubules). f, The 
frequency of each phenotype was quantified and compared between the 
wild-type and mutant proteins (Kolmogorov-Smirnov test; n=100-130 cells 
per condition from 4 independent experiments, * p<0.05, ** p<0.01, *** 
p<0.001). Red, HA; green, ubiquitin; blue, DAPI. White boxes indicate the 
regions enlarged in the insets. Scale bars: 10µm                         
 
 
72 
 
4.5 Identification of de novo mutations using a trio-based exome 
sequencing approach 
To identify further genetic factors contributing to ALS, we assessed the role 
of de novo mutations by applying the exome-sequencing approach to ALS 
trios (the proband and both unaffected parents). We selected 32 ALS trios 
of Italian origin, each patient with a diagnosis of sporadic ALS according to 
the El Escorial revised criteria [24] and testing negative for mutations in the 
main ALS-causative genes. Target cature and exome-sequencing were 
performed on a total of 96 individuals achieving an average of 3.2 x 109 
base pairs sequenced per sample to an average depth of 90.4X.    
In the filtering process, all the inherited genomic variants were excluded 
and de novo mutations (DNMs), identified as sites where both parents were 
homozygous for the reference sequence and the offspring was 
heterozygous, were reteined. DNMs were then filtered against dbSNPv135, 
the NHLBI Exome Sequencing Project and the 1000 Genomes Project to 
select only rare or novel variants, on the assumption that disease causing 
variants are unlikely to be present in controls.  
By performing a final validation with Sanger sequencing on the remaining  
candidates, we identified 25 de novo non-synonymous variants in 16 ALS 
trios and no DNMs in the remaining 16 ALS trios. The overall de novo 
mutation rate observed in our ALS trios was 0.78, consistent with those 
reported in recent WGS studies [78]. 
Among the DNMs identified, 24 were missense mutations and only 1 was a 
nonsense substitution. The list of all DNMs identified in ALS trios is 
reported in Table 11.  We did not identify DNMs in previousily known ALS-
associated genes. 
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Two variants (G358S in C10orf90 and R709W in FGD5) were found to be 
annotated in the NHLBI ESP database with a minor allele frequency    
(MAF) <0.0001, while the remaining DNMs were novel. Sixteen of the 24 
missense variants were predicted to be potentially damaging according to 
Poly-Phen-2 and SIFT score. However, none of the genes contained  
multiple DMNs among different trios or represented genes identified in  
other neurodegerative diseases or similar phenotypes.  
To narrow the list of candidate genes to prioritize, we therefore assessed 
the possible pathogenic role of DNM-containing genes by searching for 
additional mutations in FALS cases. For this analysis we used the available 
exome sequencing data from 220 Italian and US FALS patients.  
Interestingly, 30 additional novel mutations (all missense) in 17 of our 25 
DNMs-containing genes were identified in FALS (Table 12). However, none 
of the original DNMs was observed in our FALS cohort. 
Since none of DNMs containing genes has been previousily associated 
with ALS, we applied different bioinformatic tools to investigate if the protein 
products of these genes interact with each other or if they are connected to 
a set of known ALS-associated genes. A complet list of genes that have 
been associated to ALS as causative or risk factors was extracted by 
ALSOD database (available at http://alsod.iop.kcl.ac.uk/).  
Initially, protein-to-protein interaction assessment was conducted using the 
Disease Association Protein-Protein Link Evaluator (DAPPLE) tool 
(http://www.broadinstitute.org/mpg/dapple/dapple.php) on the 25 genes 
containing DNMs. In silico analysis showed one significant direct 
connectivity among two of our candidate DNMs genes, RRM33 and 
ASCC3, with a corrected p-value less than 0.05 (Figure 17). An indirect 
connectivity emerged also for 5 other genes (TJP3, SH2D3A, VPS11, 
RRP1B, LTV1). When known ALS-related genes were included in the 
analysis, the number of candidate proteins partecipating into the netweork 
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increased: RRM33 and ASCC33 showed direct connectivity with ATXN2 
(Figure 18) and other connections emerged between the candidate gene 
EPHA2 and EPHA4, identified as a modifier gene in ALS [90], and TJP3 
with GRN (Figure 18).   
We then investigated if candidate DNMs genes belonged to related 
functional pathways. Functional classification analysis was performed with 
David in our set of genes impacted by DNMs, revealing that some 
functional categories resulted enriched. In particular, 6 (TRPM4, SLC6A17, 
SLC9A5, CLCN2, VPS11 and c9orf72) out of 25 genes resulted implicated 
in transport activity, while 3 genes (ARHGEF18, FDG5, SH2D3A) showed 
guanyl-nucleotide exchange factor activity and GTPase regulator activity 
(Enrichment Score 1.36) thus having similar functions to alsin, which 
activates members of the Ras superfamily of GTPases and has been 
identified as causative of ALS. To enhance the power of bioinformatic 
analysis, 26 genes identified in 40 ALS trios from a previousily published 
study [78] were included in the analysis for a total of 51 imputs. From this 
analysis two other genes, STARD13 and KIF13A, enriched the functional 
categories “GTPase regulator activity” and “transport”, respectively. 
Interestingly, 2 (ASCC3 and ZFP64) of our genes together with other 5 
genes from the previous study  were annotated in the same cluster, being 
all involved in transcription regulation. 
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Table 11. Candidate DNMs identified in ALS trios. All variants were 
validated by Sanger sequencing in relevant  trios. The effect  of missense 
mutations was  tested by  PolyPhen-2 and SIFT. 
gene Chr aa change Mutation polyPhen ESP MAF 
ADAM33 chr20 R734X stop-gained N/A 0 
ARHGEF18 chr19 A1015T Missense benign 0 
ASCC3 chr6 D1912Y missense probably damaging 0 
C10orf90 chr10 G358S missense possible damaging 0,000077 
C8B chr1 C110F missense probably damaging 0 
CLCN2 chr3 R290Q missense probably damaging 0 
EPHA2 chr1 Q368R missense benign 0 
FGD5 chr3 R709W missense probably damaging 0,000084 
LTBP4 chr19 A1392T missense probably damaging 0 
LTV1 chr6 E296K missense possible damaging 0 
MFSD12 chr19 G28D missense probably damaging 0 
MRGPRG chr11 V101L missense benign 0 
ODZ3  chr4 P219A missense benign 0 
PAPPA chr9 V353M missense probably damaging 0 
PTCRA chr6 G280V missense probably damaging 0 
RBM33 chr7 E424A missense possible damaging 0 
RRP1B chr21 I169V missense benign 0 
SARDH chr9 P804L missense benign 0 
SH2D3A chr19 T178M missense benign 0 
SLC6A17 chr1 I142T missense probably damaging 0 
SLC9A5 chr16 R270C missense probably damaging 0 
TJP3 chr19 R162H missense probably damaging 0 
TRPM4 chr19 G238S missense probably damaging 0 
VPS11 chr11 E714K missense benign 0 
ZFP64 chr20 S399R missense probably damaging 0 
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Table 12. Novel variants in DNMs containing genes identified in a 
cohort of 220  FALS  
Gene Chr  aa change  mutation  polyPhen  
ASCC3 chr6 p.N135K missense benign 
C10orf90 chr10 p.R220P missense probably damaging 
CLCN2 chr3 p.I146T missense benign 
CLCN2 chr3 p.P738L missense benign 
CLCN2 chr3 p.R66W missense possibly damaging 
EPHA2 chr1 p.A536V missense probably damaging 
EPHA2 chr1 p.R159C missense probably damaging 
EPHA2 chr1 p.R566H missense benign 
EPHA2 chr1 p.S169P missense benign 
FGD5 chr3 p.I629V missense benign 
FGD5 chr3 p.P1325R missense benign 
LTV1 chr6 p.D65N missense probably damaging 
MFSD12 chr19 p.D475Y missense possibly damaging 
MFSD12 chr19 p.G452D missense probably damaging 
MFSD12 chr19 p.R218W missense probably damaging 
MFSD12 chr19 p.S386L missense probably damaging 
ODZ3 chr4 p.G1845R missense possibly damaging 
ODZ3 chr4 p.I594V missense benign 
ODZ3 chr4 p.M692I missense benign 
PAPPA chr9 p.H700R missense benign 
PAPPA chr9 p.N514S missense probably damaging 
RBM33 chr7 p.Q342L missense probably damaging 
RRP1B chr21 p.E218K missense probably damaging 
SARDH chr9 p.V498M missense benign 
SH2D3A chr19 p.V416I missense possibly damaging 
SLC6A17 chr1 p.G716S missense probably damaging 
SLC6A17 chr1 p.V243I missense benign 
TJP3 chr19 p.P52R missense benign 
TRPM4 chr19 p.A863V missense benign 
ZFP64 chr20 p.S578T missense probably damaging  
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Figure 17. Biological network of the direct and indirect interactions 
among gene products of our ALS trios candidate genes Colours 
indicate significance of participation in the protein-protein interaction 
network. 
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Figure 18. Biological network of the direct interactions among 
proteins from our candidate genes and known ALS-related genes 
created using using DAPPLE. Colours indicate significance of 
participation in the protein-protein interaction network. 
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5. DISCUSSION 
The recent success achieved by exome-sequencing in the identification of 
many causative genes in Mendelian disorders led to the application of this 
approach also to neurological complex diseases in which the only use of 
conventional approaches has failed. The exome-sequencing approach has 
already been applied in ALS with the identification of different novel 
causative genes, including VCP, hnRNPA2/B1 and MATR3 [76,77,89].   
Our results confirm that WES, combined with different strategies for study 
design and analysis, is an effective approach for the identification of ALS-
causing genes. 
By performing WES on two large ALS families displaying a dominant 
pattern of inheritance, we identified  causative mutations in PFN1 gene, 
which encodes for a small actin-binding protein. The reported success in 
disease-gene identification in these two families was accomplished by the 
use of a well-designed strategy: a) exome sequencing was performed on 
the two affected members of each family with maximum genetic distance, 
to select only the shared variants and to reduce the number of private 
variants to retain; b) parallel use of linkage analysis increased the efficiency 
of variant filtering by excluding variants lying outside of linkage peaks.  
The subsequent screening of PFN1 gene in a large cohort of FALS index 
cases resulted in the detection of additional mutations and assessed the 
mutational frequency of PFN1 to 2,6% in familial cases, a value 
comparable to that reported for other ALS causative genes such as VCP. 
The analysis extended to sporadic cases identified only the p.E117G 
variant in 3/1984 SALS.       
The pathogenicity of PFN1 variants in ALS was supported by three different 
genetic evidences: 1) co-segregation was assessed in three families (#1, 
#2, #3) and indicated for PFN1 mutations a high degree of penetrance; 2) 
evaluation of the evolutionary sequence conservation in conjunction with 
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different bioinformatic tools predicted potential damaging effects in terms of 
biological function; 3) three out of the 4 variants were absent in a large 
control population (more than 9000 individuals), while one variant 
(p.E117G) was detected in controls at a significant lower frequency.  
In addition to genetic data, several evidences from functional studies 
supported the predicted damaging impact of PFN1 variants.  PFN1 mutants 
formed ubiquitin-positive inclusions in transfected N2A and primary motor 
neurons, analogous to those observed for other proteins implicated in ALS, 
and showed several functional differences compared to the wild-type 
protein. In particular, a reduction of actin binding ability and an inhibition of 
axonal outgrowth were observed. Notably, in line with the genetic 
observations, the variant p.E117G exhibited only mild functional defects 
suggesting that is probably a less pathogenic mutant.  
The discovery of PFN1 further proves that the combination of traditional 
genetic approaches, such as linkage analysis, with exome sequencing 
proves is highly successful and powerful for detecting novel genes 
associated with familial ALS. 
 
Despite these advances, a wider application of this strategy for the 
identification of causative mutations in ALS is still difficult. Informative 
pedigrees, with multiple affected members available for testing, are rare for 
a neurodegenerative disease like ALS, characterized by late-onset and 
short survival time. Therefore, the adoption of novel and different analytical 
strategies that increase the probability of identifying causative rare variants 
is required to study successfully also unrelated index familial cases, which 
instead can be collected in a larger number. After performing exome-
sequencing in a large cohort of 363 index FALS, we applied  for the first 
time a novel gene-based case-control analysis to identify genes showing an 
excess of rare and predicted damaging variants in cases compared to 
controls. This strategy was designed to combine information across 
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multiple variation sites within a gene, taking into account the genetic 
heterogeneity of ALS. The approach was successful as demonstrated by 
the identification of TUBA4A, encoding for a member of the alpha-tubulin 
family, as another candidate ALS gene. The disease-related variants 
affected strongly conserved residues and most variants were absent in over 
13,000 controls. Moreover, the functional characterization of mutants 
provided strong evidence of deleterious effects on microtubule dynamics:  
a) inefficient formation of alpha/beta tubulin dimers in vitro; b) decreased 
incorporation into microtubules in cultured cells. In particular, the mutant 
p.W407X protein appeared totally deficient in forming heterodimers or in 
incorporating into the microtubule network, because of the lack of the C-
terminal region containing the binding site for beta-tubulin. Moreover, this 
mutant showed aggregation propensities analogous to those of other 
proteins implicated in ALS, suggesting that this mutations could act by a 
different pathological mechanism, such as sequestration of tubulin-binding 
proteins into the aggregates or impairment of ubiquitin-proteasome system. 
Similarly to what observed for the p.E117G variant in PFN1, the mutant 
TUBA4A p.G43V, found in a sporadic ALS case but also in a control 
individual, did not display significant functional differences from the wild-
type protein.  
 
Finally, the third strategy of WES that we applied involved a family-based 
trios design in order to identify DNMs in 32 sporadic ALS patients. In 
support of our working hyphotesis, previous studies had provided evidence 
for a significant involvement of DNMs in complex neurological diseases 
such as schizophrenia, autism, and sporadic mental retardation and more 
recently in ALS. By sequencing the exome of the patient as well as his/her 
parents, we selected de novo candidates by filtering out all inherited 
variants. The advantage of this trios-approach is that it yields a limited 
number of potential pathogenic variants, because multiple random de novo 
82 
 
events occurring within an individual are extremely unlikely and each 
exome contains an average of only 0–3 DNMs. In line with the reported 
DNMs ratio, we did not identify more than 2/3 DNMs in 16/32 trios, while we 
failed to detect DNMs in the remaining 16 samples. Bioinformatical analysis 
of the total 25 genes containing DNMs showed potential inter-connections 
and an enrichment of specific biological functions, in particular the transport 
and the GTPase regulatory activity.   
In conclusion, our discoveries further support the complexity of ALS 
genetics, characterized by a great heterogeneity, with many different genes 
causing the same disease phenotype. Interestingly both PFN1 and 
TUBA4A, identified by exome-sequencing approach in familial cases, are 
implicated in the assembly and maintenance of the cytoskeletal network. 
Profilin-1 is a ubiquitous small actin-binding protein, which catalyzes the 
ADP/ATP exchange of monomeric actin (G-actin) and the addition of ATP-
bound G-actin at the barbed (+) end of actin filaments resulting in actin 
polymerization [87,88]. The fine regulation of actin dynamics, modulated by 
many other G- and F-actin-binding proteins (ABPs), is fundamental in a 
variety of cellular process and a malfunction of cytoskeletal components 
causes several human diseases, including neurological disorders. 
Particularly, in neuronal cells the rapid assembly and disassembly of F-
actin is particularly crucial in dendritic spine for synaptic plasticity and in the 
growth cone for the axon outgrowth and guidance to specific targets during 
neuronal development. By demonstrating that ALS-related PFN1 mutants 
alter actin dynamics and inhibit axon outgrowth, we demonstrated a 
possible mechanism by which PFN1 may contribute to ALS pathogenesis. 
A similar inhibition on neurite outgrowth was observed also for mutant 
SOD1[91] and TDP-43[92], while an alteration of spine density and 
morphology was detected in primary neurons from FUS deficient mice [93].  
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These observations suggest a common pathogenic feature among different 
ALS genes. The second gene identified by WES encodes for Tubulin alpha 
4a, which is a major component of microtubules (MT). MTs are implicated 
in a large spectrum of cellular processes, from mytosis and cellular motility 
to intracellular transport and secretion. In neurons microtubule cytoskeleton 
supports the remodeling of dendritic spines in response to synaptic 
transmission, the neurite branching, the growth cone advance for axonal 
elongation and guidance, and the intracellular trafficking to the pre- and 
post-synaptic compartments [94]. Alterations of the axonal microtubule 
network seems to impair the MT-based anterograde and retrograde 
transport contributing finally to axonal swelling. The axonal transport is 
particular crucial in motor neurons, which have long axons that can extend 
for up to a meter to reach their target, and therefore any disturbance of 
axonal transport may have severe consequences on the function and 
survival of motor neurons. We demonstrated severe functional defects for 
TUBA4A mutants, including impaired heterodimerization and defective 
incorporation into microtubules, which could trigger motor neuron 
degeneration in ALS. Interestingly, mutations in other tubulin genes 
(TUBA1A, TUBA8, TUBB2B, TUBB3, TUBG1,TUBB4A) have been linked 
to several neurodevelopmental and neurodenegerative diseases [95]. Most 
mutant tubulin proteins show functional defects similar to the ones 
observed for TUBA4A mutants, such as impaired dimerization and 
microtubule incorporation, and yet cause very different phenotypes. The 
difference could be explained by a differential temporal expression of 
tubulin during development: most α- and β-tubulin genes responsible for 
developmental disorders are highly expressed early during brain 
development and decrease with age, whereas TUBA4A levels increase 
dramatically (>50-fold) with age. Furthermore, the progressive motor 
neuronopathy (pmn) mutant mouse, a commonly used model for human 
motor neuron disease, is the result of a mutation in the Tubulin-specific 
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Chaperone E (TBCE) gene [96]. A downregulation of genes encoding for α-
tubulin subunits has been reported in spinal motor neurons of SALS 
patients [97] 
The identification of PFN1 and TUBA4A as novel causative genes for ALS 
reinforces the hypothesis that cytoskeletal defects have a major role in 
disease pathogenesis. Other genes encoding for cytoskeletal proteins, 
DNCT1, PRPH, and NEFH, have been associated to ALS. From a 
neuropathological point of view spheroids inclusions containing 
neurofilaments and kinesins are found in affected motor neurons. Although 
these alterations were considered for a long time a secondary 
consequence from the neuronal degeneration, recent studies on animal 
models have demonstrated that alterations of intermediate filaments can 
trigger cell death in neurons. 
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6. CONCLUSIONS 
The identification of novel disease genes represents the first step to a 
better understanding of the pathological mechanisms and pathways 
underlying the disease, which in turn serves as a starting point for 
developing therapeutic interventions. Exome sequencing, with its unbiased-
nature, has significantly progressed and transformed ALS genetics in the 
last few years. By applying tailored study designs and strategies for variant 
prioritization in exome-sequencing, we were able to identify two novel 
causative genes, PFN1 and TUBA4A, both affecting the cytoskeletal 
network. 
In particular, exome sequencing combined with linkage analysis, has 
proven to be the highly successful approach, as demonstrated by the 
identification of PFN1 in our study and by the increasing number of ALS-
causing genes identified in the last few years.  
The second gene, TUBA4A, was identified by using a novel exome-wide 
rare variant analysis in a large sample cohort of unrelated FALS, not 
amendable to conventional approaches. The analysis, which allows to 
identify genes showing a significant excess of rare damaging variants in 
cases compared to controls, has demonstrated to be effective in ALS. 
Although TUBA4A was the top hit, the study identified other candidate 
genes, which will be further investigated by performing additional 
mutational screenings in ALS cohort and functional studies. Other genetic 
analyses are needed also for TUBA4A to assess its potential contribution to 
the genetics of FTD, in view of the ALS-FTD phenotype observed in 3 out 
of  6  mutated patients.  
 
In conclusion, exome sequencing has proven to be a robust method to 
study a disorder with great genetic and phenotypic heterogeneity like 
familial ALS. Although these advancements, it’s important to underline that 
genes identified by WES so far (PFN1, TUBA4A, VCP, MATR3, 
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hnRNPA2/B1) account only for a very small percentage of FALS cases, 
while they don’t seem to contribute significantly to the aetiology of sporadic 
forms. One future challenge will be to systematically study the role of 
variations in the non-coding regions by full genome sequencing. As 
demonstrated by C9orf72, it’s possible that causative mutations for the 
remaining genetically unknown FALS may localize in non coding regions 
which are not captured in WES.  
 
In comparison to FALS, the exome sequencing studies on sporadic ALS 
are few, although increasing evidence points to a role of rare variants for 
explaining a large part of SALS heritability. To improve the chances of 
successfully discovering rare variants associated with ALS susceptibility, 
we explored a trio-based approach aimed at the identification of  de novo 
coding mutations. Similarly to a study recently published [78], our results 
confirm that recurrently mutated genes among different trios are rare for a 
genetically heterogeneous disease like ALS. Additional in silico evaluations 
of protein-protein interactions and pathway-based analyses can provide 
supportive evidences useful for candidate genes prioritization. We are 
confident that increasing the number of ALS trios analyzed, although 
difficult for the limited availability of parental samples in an adult-onset 
disease, and integrating data from multiple similar studies will help to 
improve the disease gene discovery efforts in sporadic ALS. 
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